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Abstract 
 
 
The mechanism of HIV-1 virolytic inactivation by 
 Env-targeting peptide triazole thiols 
Laurèn D. Bailey 
Irwin Chaiken, Ph.D. 
 
 
 
The HIV-1 entry process is mediated by the interaction of the trimeric envelope 
glycoprotein (Env) on the virus membrane surface with the host cell receptors, CD4 and 
co-receptors CCR5 or CXCR4.  Each Env trimer consists of two non-covalently associated 
glycoproteins, a gp41 transmembrane protein, and an external gp120 surface protein.  
Because Env is the only virus-specific protein on the virion surface and is essential for cell 
receptor interactions and subsequent virus-cell fusion, it is an important therapeutic target 
for directly inhibiting and blocking the initial steps leading to host cell infection.  Peptide 
triazoles (PTs) are a novel class of dual antagonistic entry inhibitors of HIV-1 Env, which 
function by blocking gp120 binding to CD4 and co-receptor on the host cell.  We have 
determined that a subclass of PTs that contain a C-terminal cysteine, peptide triazole thiols 
(PTTs), cause irreversible viral inactivation and lysis.  In this work, we demonstrated that 
PTT- induced lytic inactivation is triggered by a disulfide exchange reaction between the 
peptide sulfhydryl group and conserved gp120 disulfides.  Interestingly, disulfide exchange 
is a process previously found to be necessary for fusion and entry of several viruses. 
 
To understand the mechanism of action of virolytic PTT inhibitors, my research focused 
on structure activity relationship (SAR) studies of PTTs in concert with protein chemistry 
and virus/cells analysis.  The studies were initiated by synthesizing and characterizing 
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truncated PTTs to define the distance relationship between the PT-SH groups and gp120 
disulfides.  Furthermore, understanding the lytic mechanism involved the use of gp120 
protein ligands, sulfhydryl blocking, and reducing chemicals to determine their effects on 
PTT-induced p24 release.  We determined that the PT thiol group is required for lytic 
activity and we observed a strong dependence of lysis activity on length of the linker 
between the IXW pharmacophore and SH group in PTT truncate SAR studies.  
Furthermore, we used a molecular dynamics (MD) simulation of a PTT-gp120 complex to 
identify the PT-SH point of contact region in gp120.  The MD simulation displayed the 
trajectory of the peptide SH group and suggested that it could interfere with conserved 
disulfides clustered proximal to the CD4 binding site in gp120. We next performed 
mutational analysis of these conserved cysteine residues in this gp120 region as well as 
gp41 to identify a specific contact site.  HIV-1 Env cysteine mutagenesis studies implicated 
the role of gp41 in virolytic mechanism, possibly by stabilizing six-helix bundle formation, 
due to PTTs inability to cause lysis in viral particles lacking the conserved gp41 disulfide.  
 
In the last part of this work, we synthesized a biotinylated variant of PTT used to confirm 
the covalent binding of PTT to gp120.  The biotinylated PTT was characterized and shown 
to exhibit functions comparable to that of its’ parent PTT.  When the biotin tagged PTT 
variant was incubated with gp120, the two were found to bind covalently, a feature which 
was also observed in BaL.01 virions.  Furthermore, we defined that the thiol in PTTs is 
necessary to bind gp120 covalently to exert its mechanism of action, disulfide exchange. 
Our data suggest that PTTs hijack the native HIV entry process by triggering disulfide 
exchange leading to molecular transformations of the HIV-1 trimer, which normally occur 
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upon virus-cell entry and later membrane fusion.  We infer that PTT’s undergo disulfide 
exchange between gp120 and the peptide thiol group, a process that mimics native cell 
entry.
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1. Introduction 
 
It has been more than 30 years since the first cases of Human Immunodeficiency Virus (HIV) were 
reported in the United States and in this time we have found that HIV has much in common with 
other viruses1.  We know that HIV weakens the immune system by creating a “deficient” immune 
response that cannot defend our bodies2.  However, unlike most other viruses, which the body 
usually eradicates, the human body is incapable of clearing HIV due to the continued viral 
exploitation of T cells.  Consequently, HIV- positive patients with extremely damaged immune 
systems progress from HIV to Acquired Immunodeficiency Syndrome (AIDS) 2,3.  Since its 
identification in 1981 more than 30 million people have died due to AIDS - related infections, more 
than 34 million people are currently living with HIV, and nearly 2.5 million individuals are newly 
infected each year, thereby making HIV transmission a global health concern4,5.  Although these 
numbers may seem daunting it is important to recognize how far HIV/AIDS research has advanced 
over the past 30 years.  A HIV-positive diagnosis was once thought to be a death sentence, but now 
patients can expect to live for several decades due to the introduction of a cocktail of inhibitors 
referred to as highly active antiretroviral therapy (HAART) in 1996.  Promisingly, HAART has led 
to a 70% drop in mortality rates thereby making HIV a chronic yet manageable disease, but it is 
important to emphasize that HAART is not a cure 4,5.  Due to the ever-changing nature of viruses, 
HAART is not effective in HIV positive patients that may be infected with resistant viral strains.  
Additionally, continued administration of HAART can itself lead to resistance, making the once 
effective treatment futile 6,7. There is still much research to be done and many advancements to be 
made.  
Effort has been thrust into developing vaccines, but there are currently not any vaccines which are 
capable of neutralizing the virus 8,9. Although the efforts mentioned above have displayed some 
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success in reducing HIV-1 transmission, there is still a pressing need for alternative therapies, 
prevention strategies, novel drugs, drug targets, and microbicide development.  Understanding the 
structure and function of HIV-1 Env is essential for prophylactic development because Env-
targeting drugs may have the ability to destroy virus particles before they engage target CD4 cells, 
which enhances their potential as a therapeutic. 
 
1.1  HIV-1 Life Cycle 
 
1.1.1 HIV-1 Structure and Entry: 
 
HIV-1 is an enveloped retrovirus belonging to the lentivirus genus and has a spherical shape with 
a diameter of about 120 nm, making it a rather large virus.  HIV particles are encapsulated by a 
lipid bilayer that encloses viral proteins and viral RNA (Figure 1)10,11.   In the viral particle twelve 
of these proteins are present including four Gag proteins MA (matrix), CA/p24 (capsid), NC 
(nucleocapsid), and p6.  Additionally, the two Env proteins, which are the structural components 
of the virus, are gp120 and gp41.  Furthermore, HIV contains three Pol proteins PR (protease), RT 
(reverse transcriptase), and IN (integrase), all of which provide essential enzymatic functions.  The 
accessory proteins Vpr, Nef, and Vif are also packaged into the virion.  Tat, Rev, and Vpu are gene- 
regulatory accessory proteins that aid in HIV infection and life cycle10. 
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Figure 1. Schematic depiction of an HIV particle. HIV consists of two RNA strands with associated enzymes, 
which are protected by the conical shaped p24 capsid proteins.  p24 is surrounded by the matrix protein and 
a phospholipid bilayer encloses the viral envelope from which the gp160 proteins are anchored to.  Schematic 
adapted from Charles Ang. 
 
 
The HIV viral membrane contains the trimeric envelope glycoprotein (Env).  Each Env trimer 
consists of two non-covalently associated glycoproteins, a gp41 transmembrane protein, and an 
external gp120 surface protein 12-14.  HIV Env infects vital immune cells that display CD4 receptors 
on their surface along with a chemokine co-receptor CXCR4 or CCR5, such as T cells, 
macrophages, and dendritic cells15.  Several conformational changes within Env are required to 
initiate co-receptor binding after CD4 engagement (Figure 2) 12,16.  Specifically, a bridging sheet 
conformation of gp120 is induced by the formation of two beta sheets brought together to form a 
four - stranded beta sheet.  The CD4 binding also results in the exposure of the V1/V2 and V3 loop 
structures, which orients gp120 so that the bridging sheet and V3 loop are directed toward the host 
membrane 17-19.   
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Figure 2. Schematic representation of the HIV entry process. Schematic by Andrew Holmes.  
 
 
This series of Env conformational rearrangements causes the exposure of the hydrophobic fusion 
peptide of the N terminus sequence of the transmembrane protein, gp41, the host cell membrane.   
The extended conformation of gp41 forms a “prehairpin intermediate” (Figure 3), this takes place 
when the N- terminus of gp41 inserted in the cell membrane and its C- terminus in the viral 
membrane15,20.  
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Figure 3.  Model of HIV Membrane Fusion15. The model shows the conversion of the pre-hairpin 
intermediate into the hairpin “six helix bundle” formed with one spike and folded perpendicular to the viral 
membrane. The HR1 and HR2 regions are displayed in white and blue, respectively. Copyright permission 
granted. 
 
 
The two heptad repeat regions of gp41 fold onto each other to form a stable and energetically 
favorable 6-helix bundle, thereby guiding the viral and host cell membranes adjacent to each other 
to allow membrane fusion20.  The membrane fusion process is essential for infection because it 
ensures the transmission of the RNA viral genome into the host cell along with MA, RT, IN, and 
Vpr.  This material is transported to the host cell nucleus where the viral RNA is transcribed to 
DNA by RT, next IN integrates the viral DNA into the host genome10.  It is at this point that the 
host cell is now completely exploited by HIV to produce viral components.  The integrated provirus 
DNA is transcribed into mRNA and then spliced and exported to the cytoplasm for translation into 
the regulatory protein, Tat.  Gag and Env are produced from unspliced full-length mRNA and are 
packaged into new viral particles that bud off the cell surface membrane and go on to infect more 
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cellular targets to create new progeny.  Upon budding, the capsid undergoes protease cleavage, 
which yields a mature fully infectious viral particle. 
 
 
1.1.2. Structure of HIV Envelope: 
 
The numerous intricate conformational changes that are needed for HIV entry demonstrates the 
crucial role of gp120.  Env is the only virus-specific protein on the virion surface and is essential 
for cell - receptor interactions and subsequent virus-cell fusion.  Therefore, HIV-1 Env is an 
important target to directly inhibit and thus block the initial steps leading to host cell infection. For 
this reason, Env-specific inhibitors that inactivate the virus and block receptor engagement would 
be useful for suppressing HIV-1 infection and the spread of AIDS. 
 
Gp120 is a heavily glycosylated protein.  It is extensively modified with high mannose and complex 
carbohydrates resulting in almost 50% of its molecular weight21.  Its sequence consists of five 
conserved regions (C1-C5) intertwined with five highly variable loops (V1-V5)21.  Extensive 
research has shown that the “core” gp120 is made of the conserved regions and the variable loops 
extend from the core22.  The architecture of gp120 is thought to behave as a series of layers, which 
respond and move according to its association with receptor and co-receptor23.  The “unliganded” 
state of gp120 is structurally metastable and its highly glycosylated domains are arranged in a 
manner that protects the virus from the immune system by forming a “glycan shield”23.    Only after 
receptor engagement do the layers of the “liganded” gp120 move to reveal the binding sites.  It is 
in the bound or active state of gp120 that the conformation can be divided into two separate 
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domains24.   Both domains contribute two beta sheets which converge at the bridging sheet where 
the co-receptor binds (Figure 4).  The interface of the inner domain, outer domain, and bridging 
sheet contains a deep hydrophobic cavity, whose primary binding target is the Phe43 residue of 
CD4.  The cavity is lined with highly conserved amino acids in the variable region, thereby 
exemplifying the critical nature of gp120 binding specificity to the Phe43 residue23.  In all, the 
constant conformational rearrangements and heavy glycosylation make gp120 an elusive target.   
 
 
 
 
Figure 4. Model of HIV-1 gp120 monomer activation triggered by CD4 binding.  A. The image is oriented 
to depict the viral membrane at the top of gp12025.  The image displays the gp41 ectodomain (orange), β20-
β21 loop (blue), gp120 outer domain (yellow), and the gp120 inner domain beta sandwich (red).  The inner 
domain consists of three layers; layer 1(magenta), layer 2(green), and layer 3(yellow). Inner domain 
rearrangement after CD4 binding.  V3 and β20-β21 loops move to form the bridging sheet post CD4 binding 
to allow gp120 availability for co-receptor binding. B. The structure of HIV-1 HXBC2 gp120 (ribbon) bound 
to a CD4 domain (pink surface)24.  Copyright permission granted. 
 
However, in 1998 the crystal structure of a deglycosylated gp120 “core” lacking some N and C 
termini as well as the variable loops bound to CD4 and 17b, a co-receptor surrogate, contributed to 
a much greater understanding of the structural biology of gp12024,26.  Although this structure was 
not a complete representation of HIV-1 Env, it revealed potential new gp120 sites that could be 
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targeted by inhibitors. Due to the homology between HIV and SIV many researchers have found it 
useful to compare these structures to provide answers regarding the structural conformations of 
bound and unbound gp120.  Crystal structure analysis of HIV ad SIV bound to the antibodies F105 
and b12 as well as CD4 helped to show that hydrophobic residues in the V3 loop help maintain the 
gp120-gp41 association (Figure 5)27.  Since this time several other gp120-liganded crystal 
structures have been determined which contain more domains of gp120, such as the V3 and V4 
loops and some portions of the N and C termini (Figure 5)27.   
 
 
 
 
 
 
Figure 5. Various conformations of SIV or HIV crystallographically determined structures27. (A) Unliganded 
SIV. (B) F105 Bound HIV-1. (C) b12 Bound HIV-1. (D)  CD4 Bound HIV-1.  The HIV-1 HXBc2 core gp120 
crystal structures observed in complex with Fab fragments of b12 or F105 neutralizing antibodies or with 
two-domain CD4.  The HIV-1 domains are colored as follows: outer domain (yellow), inner domain (red), 
bridging sheet (blue) [blue for β20-β21 loop and green for β2-β3 of the V1/V2 region. Copyright permission 
granted. 
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Furthermore, cryo electron tomography produced a 6 - Å membrane bound, uncleaved, and fully 
glycosylated trimer structure and crystallography has produced the structure SOSIP (pdb structure- 
4NCO), a native cleaved trimer28,29.  These detailed trimer structures have spurred the discovery of 
antibodies and the identification of immunodominant HIV envelope target sites, thereby spurring 
efforts for an HIV vaccine30,31. 
All together these newly emerging structures provide a more holistic depiction of gp120-CD4 
interactions and have been a platform to gain more detailed information about the binding 
interactions of many inhibitors.  These structures are also valuable because they are being using for 
computational modeling to develop novel drugs against the ultimate target, the HIV viral spike. 
 
1.2 HIV Entry Inhibitors 
 
HIV entry requires the coordinated conformational changes of the viral envelope spike and the 
gp41 transmembrane protein.  These intricate events allow for the initial receptor and co-receptor 
binding, fusion of the viral and host membranes, and subsequent viral integration events leading to 
HIV protein production.  The multi-step process of HIV entry has enabled researchers to target the 
life cycle from many angles, ranging from inhibiting entry, viral membrane fusion, reverse 
transcription and integration of the viral genome, all in hopes of eradicating HIV transmission. 
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1.2.1 HAART: 
 
HIV-positive patients receiving HAART are administered a cocktail of inhibitors, therefore 
controlling the plasma levels of HIV-1 RNA below detectable limits. There are more than 30 FDA-
approved inhibitors for HAART treatment, each of these inhibitors belonging to one of six classes32. 
These include protease inhibitors (PIs), fusion inhibitors (FIs), integrase inhibitors (IIs), non-
nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors 
(NRTIs), and chemokine receptor antagonists (CRAs)32.  A series of patient- specific factors go 
into deciding which inhibitors are used in HAART, such as allergies of the patient and the viral 
load based on CD4 counts. After analysis of the patient diagnosis a minimum of two inhibitors are 
used in combination since these drugs target different stages of the viral life cycle33.  However, 
there are still challenges that face HAART.  Many HIV-1 patients report serious adverse effects 
because of HAART, so many discontinue use and patients who adhere to the treatment eventually 
no longer respond to the inhibitors due to viral resistance33,34. 
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Figure 6. Mechanistic and therapeutic insights of HIV-1. Maraviroc and T20 (red) are current inhibitors that 
target HIV-1 fusion35. Maraviroc targets the CCR5 co-receptor, thereby inhibiting gp120 binding.  T20 
targets gp41, prevents six-helix bundle formation, subsequently inhibiting viral and host cell membrane 
fusion. Rosemary Bastian Dissertation 2014. 
 
 
At the onset of viral resistance to HAART, patients are switched to salvage therapy, a treatment of 
inhibitors against HIV entry and fusion.  Enfuvirtide, or T-20, is a 36 amino acid peptide that blocks 
the fusion process36 (Figure 6).  T-20 is comprised of a segment of the membrane proximal exposed 
region (MPER) of the gp41 protein.   T-20 binds to the N- terminal heptad region (N-HR) of gp41 
thereby preventing the assembly of the pre-hairpin intermediate and ultimately the six helix bundle, 
thus halting entry37. It is well documented that the N-HR of gp41 is transiently exposed, therefore 
T-20 has a limited time of action38.  However, several escape mutations in the N-HR of gp41 have 
developed, which reduce the binding affinity of T-20 by nearly 50 fold.  Side effects resulting from 
T-20 are similar to those of HAART, including diarrhea and nausea39 additionally, because T-20 is 
administered twice daily subcutaneously, skin irritations and rash at the injection sites are also 
commonly reported. Lastly, the cost of production for peptides are extremely high, therefore T-20 
is not used as a first line regimen of HAART, yet it is a salvage therapy. 
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Maraviroc is a Pfizer co-receptor inhibitor also FDA approved for salvage therapy.  The small 
molecule binds to CCR5, a G-protein coupled receptor required for most HIV-1 clades, therefore 
preventing gp120 recognition36.  Because Maraviroc solely inhibits R5-tropic viruses, candidate 
patients must initially undergo screening to confirm their co-receptor tropism.  The limited viral 
scope of Maraviroc eventually leads to escape mutations as evidenced by the emergence of X4-
tropic and X4R5-tropic viruses utilizing the CXCR4 co-receptor to gain entry into host cells40.  Side 
effects of this orally administered drug include upper respiratory infections, rashes, and dizziness. 
 
It is clear that the HAART represents the standard of care for HIV patients. However, it is also 
clear that there are still gaping holes in the field of viral entry and fusion inhibitors.  This makes 
the need even more pressing to make major strides in the development of more potent entry 
inhibitors that yield less resistance. 
 
 
1.2.2 CD4-Gp120 Interaction Inhibitors: 
 
Gp120 engagement with CD4 is a critical stage for viral entry because it represents the virus’ first 
encounter with a host cell.  Therefore, disrupting gp120’s interaction with CD4 has been at the 
forefront of HIV research.  CD4 is a protein consisting of four extracellular domains. The N-
terminal domain has a beta hairpin containing the Phe43 residue, thereby making this domain 
indispensable for gp120 binding23,41.  The crystal structure from Kwong et al. of gp120 bound to 
CD4 highlighted the highly conserved residues in the span between 25 and 64 that outline the Phe43 
cavity, importantly Arg5923. Researchers equipped with this newfound structural information of 
the g120 binding site in CD4 have made many attempts to block the CD4-gp120 interaction through 
the use of CD4 mimetics. However, this interaction has proven to be an elusive target. 
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One of the first attempts at disrupting this interaction was the development of a soluble CD4 
(sCD4), engineered by the recombinant extracellular portion of the CD4 protein. sCD4 was found 
to be a potent therapeutic when tested in laboratory inhibition studies done in vitro. However, the 
hope of this becoming a successful drug was quickly halted when it did not display any efficacy in 
clinical trials42,43.  The loss of efficacy is attributed to reduced affinity of sCD4 of primary HIV-1 
isolates due to resistance mutations.  Another approach has been to develop Phe43 cavity- targeting 
small molecules, examples include the BMS compounds and CD4 mimetics, like NBD inhibitors 
and the M33 peptide. The BMS class of inhibitors restructure gp120 making it unrecognizable for 
CD4 binding44,45.  Despite the promising potency of BMS 448043, BMS 626529, and BMS 378806, 
these inhibitors did not progress further than phase 2 clinical trials due to poor pharmacokinetics46.   
The NBD class of compounds were originally identified by a screen.  The lead drugs were improved 
upon by rational design to increase infection inhibition and gp120 binding potency47.  However, 
further analysis of the NBD inhibitors demonstrated that they restructure gp120 in a manner very 
similar to that of CD4.  This conformational entrapment of gp120 induced by NBD inhibitors led 
to enhanced co-receptor binding48,49. This was a highly disappointing result because it caused 
infection in CD4-negative cells50.  Another CD4 mimetic was the 27 residue peptide, M33.  M33 
could not have been created without the detailed structural information about the gp120-CD4 
binding interaction.  CD4 consists of a beta hairpin that is responsible for most of its interaction 
with gp120.  A structurally similar beta hairpin is found in scorpion and charybdotoxin, therefore 
the gp120 binding surface was placed onto the toxin scaffold, yielding M3350,51.  The peptide bound 
directly into the Phe43 cavity, therefore preventing viral entry.  However, its limitations were 
similar to the NBD class of compounds.  It also induced the restructure gp120 in a manner similar 
to that seen with CD4, thereby causing enhanced co-receptor binding and subsequent enhanced 
infections48,50.  
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Targeting the Phe43 cavity to disrupt the gp120-CD4 binding interaction is sought after because it 
remains one of the most highly conserved sites on gp120 where resistance mutations are unlikely 
to appear.  However, the various attempts made to disrupt this critical interaction has taught us 
several things about the binding interaction.  The efforts displayed in the era of CD4 mimetic 
development have shown that that designing Phe43 cavity inhibitors may still be a feasible route 
as long as they do not induce the gp120 structural rearrangements which allow co-receptor 
recognition and binding as we have seen that they led to enhanced infection. 
 
1.2.3 Virucidal Agents and Microbicides: 
 
Microbicides are generally pharmacologic or chemical agents that destroy microorganisms that 
cause human infection.  Microbial activity can be utilized in  numerous delivery systems, ranging 
from lotions, gels, tablets and films52.  They can exert their action by detergents and surfactants, 
polyanion attachment strategies, nanoscale dendrimers, and anti-retrovirals (ARV) delivery52,53.  
Therefore, microbicides are a potentially useful method to prevent the transmission of HIV.  Even 
further, microbicides that engage virions and cause specific viral lysis at the initial point of contact 
are known as virucidal agents.  Virolytic microbicides of HIV-1 Env work by a mechanism which 
specifically targets Env in the absence of cells, thereby making them a potential prophylactic.  
 
HIV-1 Env is of great importance for prophylactic development because these microbicides may 
have the ability to destroy virus particles before they engage target CD4 cells.  For example, 
nonoxonyl-9 (N9), a nonionic detergent, was one of the first virucidal surfactants clinically 
tested54,55.  Initially N9 was met with great promise because of its ability to disrupt viral membranes 
and because it could be manufactured cheaply.  Although the FDA deemed N9 an effective vaginal 
contraceptive, it was not until later clinical trials analyzing the efficacy of N9 for sponge, gel, or 
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film formulations found the microbicide was not acceptable for general use. The clinical trial, COL-
1492, administered between 1996 and 2000 most eloquently demonstrated precisely how 
inadequate N9 was for HIV prevention.  COL-1492 displayed an increase in the incidence of HIV 
in the N9 group relative to the placebo group56,57. In subsequent laboratory studies N9 was shown 
to induce pro-inflammatory cytokines and have poor specificity for viral membranes and also 
caused damage to vaginal and rectal mucosa.  After several surfactant microbicides failed clinical 
trials, there was a shift toward using polyanions as a microbicide source. Polyanions specifically 
bind to and inactivate viral particles, making them much more specific than surfactants.  Like 
surfactants, polyanions are also cheap to produce, yet they have the additional feature of safety.  
The two efficacy trials using polyanions, cellulose sulfate and PRO 2000, were terminated after 
data revealed that they were not efficacious and they increased the risk of HIV infection57,58.  
Nanoscale dendrimers contain a multivalent display of microbicides, which lead to reducing HIV-
1 replication upon contact.  Microbial dendrimers have served as new age inhibitors for HIV, but 
also for reducing transmission of other sexually transmitted diseases.  The broadly acting 
microbicide, VivaGel (SPL7013) was found to be a potent virucidal agent59 not only against HIV, 
but also against human papilloma virus (HPV) and Herpes simplex virus (HSV).   However, the 
utility of the microbicide varies depending on the drug toxicity to epithelial cells and the effect of 
semen on the protectiveness of the drug.  Lastly, utilizing ARVs as microbicides has proven to be 
the safest and most potent method for preventing HIV-1 infection because it is most specific to the 
virus.  The CAPRISA 004 clinical trial analyzed a gel formulation of the NRTI, tenofovir, also 
used in HAART60.  The efficacy trials of 1% tenofovir gel displayed a greater than 50% reduction 
in HIV-1 acquisition60,61.  Even more, the assessment did not display any changes to viral loads or 
adverse side effects. 
 
There is a renewed enthusiasm in the HIV field for developing microbicide agents using other 
reverse transcriptase inhibitors.  Researchers are hopeful that producing microbicides which 
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specifically target the virus will be a nontoxic mode of preventing HIV infection57,58,60,62. But, there 
are some concerns that are associated with using HAART inhibitors for microbicide treatments.  It 
is risky to use a topical or oral treatment for pre-exposure prophylaxis treatment, which in many 
cases can lead to the emergence of escape mutations.  The next goal in evolving microbicides 
should be directed towards using agents that specifically target the virus, but are not apart of current 
HIV therapy. 
 
 
1.2.4 Peptide Triazole Thiols: Novel HIV-1 Entry Inhibitors 
 
Previously, in an attempt to develop entry inhibitors, a phage display was used (8) to discover dual 
antagonists of gp120, which prevent CD4 and co-receptor binding. This effort led to the linear 
peptide precursor, 12p1 (12p1, RINNIPWSEAMM).  Modifying proline 6 of 12p1 with an azide 
and subsequent copper-catalyzed (2+3) cycloaddition reactions of the azide with substituted 
acetylenes (Click Chemistry) led to production of a series of triazole peptide conjugates (Figure 
7) with enhanced binding affinities to HIV-1 gp12063-66.  The highest affinity candidate in the 
series of peptide triazole conjugates was the ferrocene triazole conjugate HNG-156. This 
derivative and related compounds are known as peptide triazole inhibitors.  These were shown to 
bind to HIV-1 gp120 with an equilibrium dissociation constant KD of 7 nM, in contrast to the 2600 
nM KD of the 12p1 precursor.  The peptide triazole family of inhibitors binds gp120 and alters its 
conformation, thereby preventing it from engaging CD4 receptors as well as the co-receptor 
surrogate mAb 17b.  Dual receptor site antagonism likely derives from allosteric action on the 
envelope protein67,68.  In all, the HNG156 prototype of the peptide triazole class of entry inhibitors 
was found to bind to HIV-1 gp120 with nanomolar affinity65, to suppress protein ligand 
interactions at both the CD4 and co-receptor binding sites of gp12065,68 and to inhibit cell infection 
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of virus subtype A, B, C, and D isolates69. The peptide triazole does not exhibit any detectable 
toxicity in a tissue explant model at concentrations up to 100 μM69.  Additionally, peptide triazoles 
cause gp120 shedding, therefore irreversibly inactivating HIV-1 Env70.  Interestingly, a sub-class 
of peptide triazoles, peptide triazole thiols (PTTs), containing a C-terminal cysteine sulfhydryl 
group were found to cause viral lysis, evidenced by p24 release along with gp120 shedding. 
 
 
 
 
 
 
 
 
Figure 7. Conversion of linear peptide, 12p1, to peptide triazole, and next generation peptide triazole thiols.  
Ferrocenyl conjugates attached the Azido proline residue by Click Chemistry to generate potent peptide 
triazoles. 
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We have conducted site - directed mutagenesis experiments of the CD4 binding pocket of gp120 
to identify the binding footprint of peptide triazoles with HIV-1 Env.  Mutations in the residues of 
the inner and outer domain (D474A, T257A, and S375W) have shown a reduced binding affinity 
to peptide triazoles70, therefore implicating their roles in initiating contact with peptide triazole 
inhibitors (Figure 8).   
 
 
 
 
 
 
Figure 8. Functional epitope of PT in the context of gp120 in the mAb F105 bound state. Residues critical 
for PT binding are highlighted71. 
 
 
Thus, peptide triazole inhibitors bind to gp120, close to the Phe43 binding pocket, utilizing 
conserved residues in this region to alter its conformation, therefore preventing Env’s recognition 
of both CD4 and co-receptor68,72.  To further elucidate the role of these conserved residues we 
performed additional mutations (D474A, D474E, T257A, T257S, M475A, and S375W) in gp160 
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to determine their effects in cell infection and virolysis assays71. We have shown that peptide 
triazoles target HIV-1 Env specifically through conserved residues near the CD4 binding pocket, 
whereby the entry inhibitors undergo interactions with gp120 which disturbs the viral membrane.  
However, the events that cause viral membrane rupture are unknown.    
 
The conformational entrapment trajectories induced by peptide triazole thiols will allow us to 
understand which Env epitope interactions and structural transitions lead to the most effective 
neutralization of the virion.  Further, understanding the virolytic mechanism by analyzing disulfide 
exchange reactions will identify residues of Env that need to be targeted to optimize our entry 
inhibitors. The gp120 shedding and virucidal action of peptide triazoles has potential therapeutic 
use by preventing AIDS transmission and treating HIV-1 infected patients.  The use of virolytic 
peptide triazoles as a potential therapeutic is based on their ability to inactivate virus before it 
engages host cells and the antigenicity of the retained gp41 on the residual virus particle.  In the 
latter regard, peptide triazole thiols may possibly be used as an immunogen to develop an HIV 
vaccine. 
 
 
1.3 The Biological and Biochemical Importance of the Sulfhydryl 
 
 
Of the 20 proteinogenic amino acids, cysteine is special.  Cysteine contains a reactive sulfhydryl 
group which is made possible by the sulfur atom found on its side chain, thereby making it a sulfur 
amino acid73.  Methionine is also a sulfur amino acid, however its sulfur atom is attached to a 
methyl group which makes methionine more hydrophobic and the thiol less reactive than the one 
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found in cysteine.  The reactivity of the sulfhydryl group on cysteine allows for the facile formation 
of a disulfide bond created by the oxidation of two bridging cysteines.  This dimer of cysteine 
residues linked by a disulfide bond is referred to as a cystine, whose role is crucial in protein 
structure.  Because of cysteine’s thiol reactivity it is a potent nucleophile which can participate in 
disulfide-exchange, alkylation, and peptide hydrolysis reactions.  In addition to the sulfhydryls role 
in protein structure, it also contributes to many biological processes by regulating enzymatic 
activity73.  Further, more recently it has been shown that viruses maintain a balance of thiols and 
disulfides in a mechanism called, thiol-disulfide exchange, as another means to regulate the viral 
entry process. 
 
 
 
1.3.1 Role of Cysteine and Sulfhydryls in Protein Structure  
 
Protein structure and function are based on the protein’s primary structure, which consists of the 
amino acid sequence and topology of disulfide bridges. The pattern of disulfide bridges is important 
to the three dimensional structure of the protein because they influence stability of secondary and 
tertiary structures, such as helices.  For example, some proteins contain cysteine residues which are 
not involved in a disulfide, in this case the sulfhydryl group of the cysteine residue stabilizes alpha 
helix formation.  However, more commonly cysteines are frequently found in pairs due to their 
propensity to form disulfides73.  The strong forces which hold together the disulfide cause 
secondary structure motifs, such as “turns” and “loops”73.  Of these motifs created by disulfides is 
the cystine knot.  This protein structural motif is comprised of six cysteine residues, yielding three 
disulfide pairs and leading to the formation of several loops of polypeptide.  The cystine knot motif 
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provides great stability to proteins across many species, including spider and snail toxins as well 
as plant cyclotides.  
 
The cleavage and reformation of disulfides alter the stability of the tertiary structure, and without 
disulfide bridge formation between several protein chains, quaternary structure would not be 
possible. For this reason, disulfides are often referred to as “molecular staples” due to their ability 
to maintain structural motifs which are critical to the proper folding and subsequent function of 
proteins.  The essential role of disulfides in reinforcing protein conformations, paired with the 
highly conserved nature of cysteine residues, explains why cysteines and disulfides are frequently 
used as regulatory tools. 
 
 
 
1.3.2 Role of Cysteines and Sulfhydryls in Enzymatic Activity 
 
Not only do cysteines contribute to the structural integrity of proteins, they are also involved in 
enzyme catalysis and affect in vivo redox potential, which influences downstream cellular 
processes and mechanisms 73-75. For these reasons, cells maintain a distinct thiol/disulfide balance, 
in order to regulate biological processes.  Cysteine is required for the activity of the thiol protease 
class of enzymes due to a reactive cysteine sulfhydryl group in the catalytic site. This feature is 
necessary to initiate the reaction with the substrate.  Blocking a reactive sulfhydryl group, whether 
because of its use as a mixed disulfide, oxidation, or alkylation, can result in enzyme inactivity 
(71). There is a variety of classes of enzymes which use cysteine residues to exert and regulate their 
mechanisms.  The thiol proteases, HIV protease, papain and caspases utilize their cysteinyl residues 
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for nucleophilic attack during peptide cleavage and the metabolic enzyme responsible for key 
regulatory steps in glycolysis, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), contains a 
cysteine residue in its active site.  Not only does the thiol in the catalytic site of GADPH have a 
direct influence on ATP production, but its activity is involved in transcriptional activation, vesicle 
shuttling from the ER to Golgi, and the initiation of apoptosis 76,77.   
 
The equilibrium between the reduced and oxidized state of cysteine’s sulfhydryl group impacts the 
redox potential in biological systems74,75.  For example, the tripeptide antioxidant, glutathione, 
contains a cysteine residue which enables the peptide to maintain reduced cytoplasmic proteins75.  
This process oxidizes glutathione yielding glutathione disulfide, however NADPH is used as an 
electron donor to regenerate the reduced glutathione reductase peptide.  The ratio of reduced and 
oxidized forms of NADPH goes on to regulate biosynthetic reactions, such as cholesterol and lipid 
synthesis.   
 
The redox state of thiols affects further downstream events, such as post-translational 
modifications.  Phosphorylation events are affected by redox modulation since oxidative 
environments inhibit phosphatase activity, which directly influences protein signaling73.  Lastly, 
numerous processes require signal transduction which is transmitted through dimerized proteins 
made possible through the formation of a disulfide bond between the two protein subunits.  The 
formation of the disulfide bond may require the oxidation of the cysteine in one subunit and the 
condensation of a cysteine in the other subunit, which is determined by the redox modulation73. 
 
Therefore, cysteine’s role is vast because of its utility as a strong reducing factor and its thiol 
nucleophilic reactivity, thereby enabling it to act readily act as immediate “switch” to turn on and 
off enzyme activity as well as affect downstream processes.  These attributes make the use of thiols 
essential as a regulatory action.  
24 
 
 
This work provides evidence HIV entry utilizes thiol/disulfides for regulation, through a 
mechanism called “disulfide exchange”, a process shown to be involved in several viral entry 
processes. Thiol- disulfide exchange is a reaction of a thiol interacting with and disrupting a 
disulfide to form a new disulfide and subsequently produces a newly derived thiol (Figure 9) 73,74,78.   
 
 
 
 
 
 
 
Figure 9. Cartoon depicting in the mechanism of thiol-disulfide exchange.  For oxidoreductase cleavage, the 
active site sulfur ion nucleophile of the oxidoreductase attacks one of the sulfur atoms of the allosteric 
disulfide bond. The mixed disulfide then releases the oxidized oxidoreductase and the substrate protein 
contains a reduced allosteric disulfide.  Pink circles represent gp120 containing disulfides and blue squares 
represent an oxidoreductase, which has a reactive thiol that initiates the disulfide-exchange mechanism. 
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CHAPTER 2:  Exploring the Spatial Relationship between the Binding 
Pharmacophore and Sulfhydryl structural motifs of Peptide Triazole Thiols 
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2. Introduction 
 
Inhibiting HIV-1 cellular entry remains an enticing strategy for HIV-1 intervention and prevention.  
The entry process is mediated by the interaction of the trimeric envelope glycoprotein (Env) on the 
virus membrane surface with the host cell receptors, CD4 and co-receptors CCR5 or CXCR4. 
Because Env is the only virus-specific protein on the virion surface and is essential for cell receptor 
interactions and subsequent virus-cell fusion, it is an important target for directly inhibiting and 
blocking the initial steps leading to host cell infection.  Our lab previously developed a novel class 
of dual antagonistic peptide inhibitors of HIV-1 Env.  Upon binding gp120, the peptide triazoles 
alter gp120 conformation to an inactive state, thereby disrupting protein-ligand interactions. These 
peptides potently inhibit cell infection and cause gp120 shedding from the virus. In addition, a 
subclass of PTs containing a free sulfhydryl group (SH) at the C terminus, denoted peptide triazole 
thiols or PTTs, was found to be virucidal as evidenced by release of the p24 capsid protein from 
the virus lumen.  Here, we investigated the spatial relationship between the gp120-binding 
pharmacophore Ile-ferrocenyltriazolePro-Trp (denoted IXW) and the peptide C-terminal cysteine 
(Cys) residue that is required for lytic inactivation. 
 
An obligatory dimer of KR13 formed by crosslinking of the Cys in KR13 with a bis-maleimide 
crosslinker did not cause viral lysis, although it did retain the ability to bind gp120 demonstrating 
that lysis requires the free Cys SH.  PTT’s with serially shortened linkers between functional groups 
IXW and CysSH were synthesized and their relative lytic activities vs. gp120 binding functions 
were determined.  From a comparison of p24 release and antiviral activity, we observed a strong 
dependence of lysis activity on the length of the linker between the IXW pharmacophore and SH 
group.  Molecular docking of PTT onto gp120 argued that, with sufficient linker length, the peptide 
SH could approach several gp120 disulfides.  Furthermore, by performing competition p24 assays 
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with several distinct gp120 ligands, we found that the disulfide cluster located at the base of the V3 
loop may have a role in PTT-induced disulfide disruption. 
 
The results of our structure-activity analysis studies resulted in a greater understanding of the 
characteristic motifs of PTT required for lysis.  We found that there is a required minimum C-
terminal linker length after the pharmacophore residues, additionally the linker must terminate with 
a free C-terminal thiol group, which strongly supports the hypothesis that the p24 release of PTTs 
is promoted by disulfide exchange.  Overall, the findings suggest that PTT binding, via its IXW 
pharmacophore residues, positions the peptide SH group to interfere with conserved disulfides 
clustered proximal to the CD4 binding site in gp120.  It is possible that the close proximity of the 
peptide thiol group could lead to a rearrangement of the Env protein spike and ultimately disruption 
of the viral membrane.   
 
2.1 MATERIALS AND METHODS 
 
2.1.1 Peptide Synthesis and Click Conjugation  
 
All sequences and denotations of peptides reported are given in Table 1.  Peptides were synthesized 
manually by stepwise solid-phase peptide synthesis (SPPS) (Figure 10) on a Rink Amide Resin 
(NovaBiochem) with a substitution value of 0.25 mmole/gm as described previously72.  The 9-
fluorenylmethoxycarbonyl (Fmoc) group was employed for protection of the α-amino group during 
coupling steps.  All α and β Fmoc amino acid derivatives and coupling reagents were purchased 
from Chem-Impex International, Inc.  Side chain protecting groups were triphenylmethyl (Trt) for 
Asn, tert-butyl (tBu) for Ser and tertbutyloxycarbonyl (Boc) for Trp.  Synthesis grade solvents were 
used in all procedures.  Coupling of each residue was carried out using N, N, N′, N′-tetramethyl-
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O-(1H-benzotriazol-1-yl) uronium hexafluorophosphate (HBTU) / hydroxybenzotriazole (HOBt) 
in dimethylformamide (DMF).  Four equivalents of each Fmoc protected amino acid were used for 
coupling.  The [3+2] cycloaddition reaction with ethynyl ferrocene (Sigma Aldrich) was carried 
out by an on-resin method.  Completed peptides were cleaved from the resin by using a cocktail of 
95:2:2:1 trifluoroacetic acid/1, 2-ethanedithiol/water/thioanisole.  Crude peptides were purified 
using a semi-preparative column (Phenomenex Jupiter 10u C4 300A 250 x 10 mm, 3 ml/min) by 
HPLC (Beckmann Coulter, System Gold 126 Solvent Module and 168 Detector, 280 nm) with 
gradient between 95:5:0.1 and 5:95:0.1 water/acetonitrile/trifluoroacetic acid.  Peptide purity and 
mass were confirmed using an analytical HPLC column (Phenomenex Luna 5u C18 100A 250 x 
4.6 mm, 1 ml/min) and MALDI-TOF mass spectrophotometry, respectively (Appendix Figures 1-
30). 
 
 
 
 
 
Figure 10. Scheme of Solid Phase Peptide Synthesis (SPPS). Peptide synthesis was performed on rink amide 
resin using Fmoc-α-amine-protected amino acids. 
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2.1.2 Chemoselective Ligation of KR13 by Bis-Maleimide  
 
2.084 mg KR13 (1) (2.5 eq) was dissolved into 1000 µL of degassed phosphate buffer (50 mM, pH 
6.6) prior to the addition of 0.574 mg Tris (2-carboxyethyl) phosphine hydrochloride (TCEP⋅HCl) 
(5 eq) (Thermo Fisher Scientific) to the reaction vessel.  Peptide 1 was reduced with TCEP for 30 
min under vacuum and nitrogen purging.  400 µL of 0.522g of Bis-Mal-dPeg3 (Quanta Biodesign 
Limited) dissolved into 1000 µL ACN (1 eq) was added dropwise to the reaction vessel.  The 
ligation process was monitored by analytical HPLC (Phenomenex Luna 5u C18 100A 250 x 4.6 
mm, 1 ml/min) over a 30-95% ACN gradient, as the reaction mixture was stirred under N2 at 37 °C 
for 2 hrs.  After 2 hours, another 200 µl of Bis Mal dPeg was added to the reaction.  Peptide purity 
and mass of the final ligation product, (1a, Peptide 1 dimer), were confirmed using analytical HPLC 
(Phenomenex C18) and MALDI-TOF mass spectrophotometry, respectively. 
 
2.1.3 Virus Infection Inhibition Assays   
 
Modified human osteosarcoma cells engineered to express CD4 and CCR5 (HOS.T4.R5), as well 
as the vector for pNL4–3.Luc+ R- E-, were obtained through the NIH AIDS Repository from Dr. 
Nathaniel Landau,  while the vector expressing the CCR5-targeting spike protein BaL.01 gp160 
was obtained through the NIH AIDS Repository from Dr. John Mascola.  The recombinant virus 
was produced by co-transfecting HEK-293T cells with the proviral envelope plasmid HIV-1BaL 
strain and the plasmid encoding the backbone sequence corresponding to an envelope-deficient 
pNL4–3.Luc+ R- E- provirus. Post-transfection (72 hours), pseudovirus-containing supernatant was 
collected, filtered through a 0.45 µM syringe filter and concentrated using an Amicon spin filter 
(100 kDa MWCO) prior to being loaded on an Iodixanol gradient ranging from 6% to 20% in 
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phosphate-buffered saline (PBS)79.  Samples were spun for 2 hours at 112,000 x g on an SW41 
rotor in a Beckman Ultracentrifuge at 4 °C.  Fractions containing the pseudovirus were collected, 
aliquoted in serum-free media and frozen at -80 °C.   
 
Prior to cell infection experiments, virus samples were titered for p24 content and infectivity as 
described below.  The viral stocks were first incubated with serial dilutions of the peptide at 37 °C 
for 30 min and then added to 96 well tissue culture plates, with HOS.T4.R5 cells, pre-seeded for 
24 hrs at 8,000 cells per well.  After 48 hours infection, with a growth medium wash step 24 hours 
post-treatment, the cells were lysed with passive lysis buffer (Promega) followed by 3 freeze–thaw 
cycles.  Luciferase assays were performed using 1 mM d-Luciferin salt (AnaSpec) as substrate and 
detected on a 1450 Microbeta liquid scintillation and luminescence counter (Wallac and Jet).  The 
single-round, pseudoviral infection luciferase reporter assay was conducted as previously 
described69.  Nonlinear regression analysis was performed using Origin v.8.1 (OriginLab, 
Northampton, USA) to calculate the IC50 values.  All experiments were performed at least in 
triplicate and results were expressed as relative infection with respect to cells infected with virus in 
the absence of inhibitor (100% infected). 
 
2.1.4 Competition ELISA   
 
The ability of peptides to inhibit sCD4 and mAb 17b binding to HIV-1YU2 gp120 was analyzed by 
competition ELISA72.  First,  100 ng of HIV-1YU2 gp120 was adsorbed per well at 2 ng/µl to a 96-
well high binding polystyrene plate (Fisher Scientific) for 12 hrs at 4 °C.  The HIV-1YU2 gp120 was 
removed from the plate and blocked with 200 μL/well of 3% bovine serum albumin (BSA) 
(Research Products International, Corp) in 1× phosphate buffered saline (PBS) for 2 hours at 25 
°C, followed by plate washing 3 times with 1× PBS containing 0.1% Tween-20 v/v (PBS-T).  For 
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the CD4 competition experiments, 100 μL of 30 nM sCD4 was added to each well in the presence 
of increasing concentrations of peptide.  This and all subsequent incubation steps were done in 
0.5% BSA in PBS.  After a 1 hour incubation period, the plate was washed 3 times with PBS-T 
followed by addition of 100 μL/well of biotinylated anti-CD4 antibody (eBioscience) at a 1:5000 
dilution and the plate incubated for an additional 1 hour at 25 °C.  After plate washing, streptavidin-
bound HRP (AnaSpec) was added at a 1:5000 dilution and again incubated for 1 hour at room 
temperature.  To determine effectiveness of peptides to inhibit antibody binding to gp120, 100 μL 
of 15 nM mAb 17b was added to the plate-immobilized gp120 in the presence of increasing 
concentrations of peptide.  After a 1 hour incubation at room temperature, the plate was washed 3 
times with PBS-T, followed by the addition of a horse radish peroxidase (HRP)-conjugated goat-
antihuman antibody (CHEMICON) which was incubated for 1 hour at room temperature.  The 
extent of HRP conjugate binding was detected in both assays by adding 200 μL of o-
phenylenediamine dihydrochloride (OPD) (Sigma-Aldrich) reagent for 30 min followed by 
measuring optical density (OD) at 450 nm using a microplate reader (Molecular Devices).  IC50 
values were determined using non-linear regression analysis with Origin v.8.1 (Origin Lab, 
Northampton, USA). 
 
2.1.5 Optical Biosensor Binding Assays   
 
Surface Plasmon Resonance (SPR) kinetic interaction experiments were performed on a Biacore 
3000 (GE) optical biosensor instrument.  A CM5 sensor chip was derivatized by amine coupling 
using N-ethyl-N-(3-dimethylaminopropyl) carbodiimide/N- hydroxyl-succinimide with either 
soluble CD4 or 2B6R (antibody to human IL-5 receptor α as a control).  Each of the ligands, sCD4 
or 2B6R, were immobilized on the CM5 senor surface chip at a density of 2000 RU.  For sCD4 
competition experiments, serial dilutions of the peptides with a constant concentration of HIV-1YU2 
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WT gp120 (200 nM) were injected over the sCD4 surface.  The indicated analytes were injected 
over the surface at a flow rate of 100 µl/min with a 2.5 min association phase and a 2.5 min 
dissociation phase.  Surfaces were regenerated with 10 mM HCl injection for 3 seconds.  All 
experiments were conducted at 25 °C in filtered and degassed PBS pH 7.4 containing 0.005% 
Tween 20.  SPR data analyses were performed using BIAEvaluvation 4.1.1 software (GE 
Healthcare).  The responses from the buffer injection, and responses from the control surface to 
which the mAb 2B6R was immobilized, were subtracted to account for non-specific binding.  
Experimental data were fit to a 1:1 Langmuir binding model.  The average kinetic parameters 
generated from a minimum of 3 data sets were used to define the equilibrium dissociation (KD) 
constant.  The evaluation method for SPR inhibition data included a calculation for the inhibitor 
concentration at 50% of the maximal response (IC50).  The inhibition curve was converted into a 
calibration curve by the using a fitting function.  Data were fit to a four-parameter sigmoidal 
equation in Origin v.8.1 (Origin Lab, Northampton, USA). 
 
2.1.6 Virolysis Assays   
 
The ability of the peptide triazole thiols to cause virolysis of pseudotyped HIV-1BaL virus was 
analyzed by quantifying p24 release.  An equal volume of intact pseudotyped HIV-1BaL, purified 
through gradient centrifugation, was added to a series of samples that contained a 1:4 serial dilution 
of peptide triazole thiols as well as non-lytic HNG156 at working concentrations determined from 
the cell infection assays.  The control samples replaced the peptide with either phosphate-buffered-
saline (PBS) (negative lysis control) as well as 1% Triton-X 100 (positive lysis control).  All 
prepared samples were incubated for 30 min at 37 °C prior to a 2 hr spin at 16,000 x g and 4°C on 
a tabletop 5424R centrifuge (Eppendorf).  The top 120-µL soluble fraction was collected and tested 
for p24 content by sandwich capture ELISA as follows.  High binding polystyrene ELISA plates 
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(Fisher Scientific) were coated with 50 ng/well of mouse anti-p24 (Abcam) followed by blocking 
with 3% BSA for 2 hr at room temperature.  This was followed by PBS-T rinsing three times for 5 
min each time.  Then the soluble fractions obtained from the peptide treated HIV-1BaL diluted in 
1:100 using 0.5% BSA, were loaded onto the plate and incubated for 2 hr.  The p24 in the soluble 
fractions was quantified using 1:5000 dilutions of anti-rabbit p24 (Abcam) and then anti-rabbit IgG 
fused to horseradish peroxidase (HRP) (Invitrogen).  The activity of the HRP conjugate binding 
was determined by adding 200 µL/well of o-phenylenediamine dihydrochloride (OPD) (Sigma-
Aldrich) reagent for 30 min followed by measuring optical density (OD) at 450 nm using a 
transmission plate reader (Tecan, Infinite F50).  The PBS treated virus signals were subtracted; net 
signals were then plotted as a function of p24 release, using the fully lysed virus control, treated 
with 1% Triton X-100, as the 100% value.  Nonlinear regression analysis was performed using 
Origin v.8.1 (OriginLab, Northampton, USA) to calculate the EC50 values.  All experiments were 
performed at least in triplicate.  
 
2.1.7 Protein expression and purification of CVN   
 
The CVN plasmids were transformed into BL21 (DE3) pLysS cells and scaled-up LB media.  
Protein expression was induced using 1mM isopropyl-B-D-thiogalactopyranoside (IPTG) for 9 hrs 
a 30 °C.  In order to perform extraction of periplasmic proteins from the bacterial membrane, the 
cell suspension was pelleted and lysed before being sonicated using a microtip probe (Misonix 
3000).  The sonicated sample was spun down for 30 min at 10,000 x g to separate the bacterial 
debris from the protein containing supernantant.  The protein was then purified by gravity flow 
affinity chromatography with nickel-nitriloacetic acid (Ni-NTA) beads (Qiagen), followed by gel 
filtration with a 26/60 Superdex 200 prep - grade column (GE Healthcare) using an AKTA fast 
protein liquid chromatograph (FPLC, GE Healthcare).  Western blotting of the Ni-NTA and gel 
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filtration elution fractions along with enzyme - linked immunosorbent assays (ELISA) analysis 
were used to track protein content of eluates and functionality, respectively.  Fractions containing 
target proteins were concentrated and buffer exchanged to phosphate-buffered saline pH 7.4 using 
a 5,000 molecular weight cut-off (MWCO) spin filter (Amicon).  The final protein was examined 
on a 15% SDS-PAGE gel using Commassie blue and silver staining.  Western blot analysis using 
a rabbit anti-CVN (Biosyn Inc.) was used to confirm the presence of the CVN component.  The 
final concentration was determined using absorbance at 280 nm and an extinction coefficient at 280 
nm of 39,740 M-1 cm-1.  Cyanovirin-N and gp120 were produced in E.Coli and CHO (Chinese 
hamster ovary cells respectively, as previously reported80,81. 
 
 
2.1.8 Assays for Protein Inhibition of Virolysis   
 
The neutralization EC50 values of gp120 protein ligands were used as the starting concentrations 
for measuring inhibition of virolysis82,83.  Serial dilutions of 2G12 antibody starting at 1 mg/mL, 1 
µM of Cyanovirin, or 100 µg/mL of 697-30D antibody were incubated with the EC80 concentration 
of peptide, namely 10 µM peptide 1, 14 µM peptide 2, and 50 µM peptide 8.  The peptide and 
protein were added to a 1:4 working dilution of the purified pseudotyped HIV-1BaL virions for 30 
min at 37 ºC.  The soluble fraction was separated, and the extent of p24 release was determined by 
the same protocol as the sandwich ELISA protocol described above.  Virus in PBS was the negative 
control, while virus in 1% Triton-X 100 was the positive control.  Quantified values from triplicate 
assays were plotted as a function of p24 released compared to the positive control.  These values 
were fit using Origin v.8.1 (Origin Lab, Northampton, USA) to determine EC50s.  
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2.1.9 Gp120 Shedding Assay  
 
Serial dilutions of peptide triazole thiols 1, 2, 4, 7, and 9 starting from 50 µM were incubated for 
30 minutes at 37 ºC with a 1:4 working dilution of the purified pseudotyped HIV-1BaL virions.  
Next, the virus-peptide mixture was spun for 2 hr at 16,000 x g and 4 °C on a tabletop 5424R 
centrifuge (Eppendorf).  Negative and positive control samples included, respectively, virus in PBS 
and virus in 1% Triton X-100.  Next, 120 µl was removed from the soluble fraction to separate the 
viral pellet fraction.  Western blot analysis with an anti-gp120 D7324 (Aalto) was used to quantify 
the amount of viral envelope gp120 retained in the pellet.  The western blots were quantified using 
Image J software, and compared to the blots for the lysed virus fraction.  Data for amount of gp120 
shed from virus were analyzed by non-linear regression analysis with Origin v.8.1 (Origin Lab, 
Northampton, USA) to determine shedding EC50 values. 
 
2.1.10 Origin Pro. 8 curve fitting of dose dependence data 
 
Data analysis of dose-dependence measurements performed in this study was conducted by 
sigmoidal curve fitting using the Origin v.8.1 (Origin Lab, Northampton, USA) software.  The 
formula used, which enables a sigmoidal logistic fit, was  
𝑦 =
𝐴1 − 𝐴2
1 + (
𝑋
𝑋0
)
𝑝 + 𝐴2 
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where A1 is the initial value (0), A2 is the final value (based on the experimental data), p is the Hill 
coefficient, x is the concentration of the inhibitor used and X0 is the IC50 value.  The logistic nature 
of the fitting algorithm allows the p value to float freely.  The differences in cooperativity we 
observe in the fitted plots likely arise from complexities of the peptide-virion and virion-cell 
interactions, a situation which is different than simple protein- protein and protein –peptide 
interactions. 
 
 
2.1.11 Molecular Docking 
 
Peptide preparation for docking: 
Peptide 8 was prepared and drawn using VIDA 4.2.0 (Openeye Scientific Software, Santa Fe, NM. 
http://www.eyesopen.com).  The ferrocene containing peptide was energy-minimized using the 
MM2 forcefield (ChemBio3D Ultra 13.0) with RMS gradient of 0.001 and 104 alterations.  The 
minimized structure was saved as a pdb file, and autodock tools graphical interface (Autodock tools 
1.5.6rc3)84 was used to prepare the minimized structure of 8 for docking. 
 
Flexible docking: 
The starting point for peptide 8 flexible docking to gp120 was the previously developed model of 
PT interactions using the F105 bound crystal structure of gp120 (PDB code 3HI1)85.  The gp120 
structure was extracted from this complex and was further energy refined using Szybki 1.8.0.2 
(Openeye Scientific Software, Santa Fe, NM. http://www.eyesopen.com).  The option (-max_iter) 
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in Szybki was set to 106 to make sure that the added hydrogen atoms are correctly optimized.  The 
optimized gp120 structure was then prepared by Autodock tools graphical interface (Autodock 
tools 1.5.6rc3)84, where non-polar hydrogen atoms were merged, Kollman charges added and 
Gasteiger charges calculated.  Trp112 residue was set to be flexible for the docking such that the 
indole side chain can move during the docking simulation to accommodate the bulky ferrocene 
moiety.  The grid box for the docking search was set to 52 x 52 x 52 points for the x, y and z 
dimensions with a spacing grid of 0.375 Å.  Grid centers X, Y and Z were set to 55.784, 28.301 
and -21.068, respectively.  AutoGrid 4.2 algorithm was used to evaluate the binding energies 
between the peptide and gp120 and to generate the energy maps for the docking run.  For docking 
8 with gp120 in a high accuracy mode, the maximum number of evaluations (25X106) was used.  
Fifty runs were generated by using Autodock 4.2 Lamarckian genetic algorithm84 for the searches.  
Cluster analysis was performed on docked results, with a root-mean-square tolerance of 2.0 Å.  
Visual inspection of the docked poses was done and compared to the mutagenesis analysis 
results71,86 to select a low energy representative binding mode.  The complex was then typed with 
the CHARMM forcefield with Discovery Studio 4.0 software (Accelrys Software Inc.: San Diego, 
CA, 2013) to relax the obtained pose within the protein pockets, visualized by VIDA 4.2.0 
(Openeye Scientific Software, Santa Fe, NM. http://www.eyesopen.com). 
 
2.1.12 2G12 Mechanism of Action Infection Assay 
Modified human osteosarcoma cells engineered to express CD4 and CCR5 (HOS.T4.R5), vector 
for pNL4–3.Luc+ R- E-, as well as the recombinant virus was produced as previously explained. 
To allow HIV viral engagement with CD4 and co-receptors yet halt fusion, the initial part of the 
assay was performed under chilled conditions at 4 °C. The latter part of the assay was conducted at 
37 °C to facilitate viral fusion. Viral stocks, growth medium, and HOS.T4.R5 cells, pre-seeded for 
24 hrs at 8,000 cells per well, were pre-chilled to 4 °C. The virus was then incubated with the pre-
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chilled cells for 4 hrs at 4 °C.  The media was removed and cells were washed twice with freshly 
chilled growth medium to remove unbound virus. Then serial dilutions of 2G12 prepared in chilled 
medium and 1X PBS were incubated with cells at 30 min increments at 4 °C, then 23 °C, followed 
by a 37 °C incubation for 24 hrs, which concluded with a growth medium wash step.  After 48 
hours of infection the cells were lysed with passive lysis buffer (Promega) followed by 3 freeze–
thaw cycles. The 6-helix bundle peptide, Enfurvutide (T20), was used as a control inhibitor for 
fusion.  The luciferase activity for the infection assay was performed as described above. All 
experiments were performed at least in triplicate, and results were expressed as relative infection 
with respect to cells infected with virus in the absence of inhibitor (100% infected). 
 
2.2 RESULTS 
 
2.2.1 Synthesis and Characterization of Obligatory Dimer  
 
Previous studies have shown that luminal p24 release is a phenotype of peptide triazoles containing 
a C-terminal thiol. The non-sulfhydryl containing peptide, (10, HNG156) (Figure 12A) and 
sulfhydryl blocked derivative, KR13b, do not cause viral lysis although they potently shed gp120 
and inhibit infection70.  We employed Michael Addition chemistry to crosslink the Cys residues of 
two monomers of peptide 1 using a bismaleimide linker to produce an obligate dimer, peptide 1a 
(Table 1 and Figure 11).  We compared the effects of 1a with control peptide 1 on gp120 binding, 
HIV-1 inhibition, and virolytic properties.  Surface plasmon resonance (SPR) interaction analysis 
displayed that 1a binds gp120 with affinity comparable to that of the control, 1, seen by KD values 
found to be 2.71 ± 1.4 nM and 3.02 ± 0.9 nM, respectively (Figure 12).  Additionally, peptide 1a 
was a potent inhibitor of HIV-1 infection as evidenced by pseudotyped HIV-1BaL antiviral assays, 
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but did not cause p24 release (Figure 13).  These results reaffirmed the requirement of a free 
sulfhydryl group for virolysis. 
 
 
 
 
 
 
 
 
 
Figure 11. Structures of 10, 1 and 1a. (A) 10 is the non-lytic parental peptide triazole. (B) 1 is the lytic parent 
peptide of the library of peptide triazole thiol truncates.  All PTs contain the signature pharmacophore, 
Isoleucine (magenta)-AzidoProline (blue)-Tryptophan (green).  (C) Peptide 1a is composed of Bis-Mal dPeg 
conjugated to the C-terminal sulfhydryl groups of two monomers of 1. 
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Figure 12. Functional Characterization of PTT dimer, 1a. (A) Direct binding was measured to chip-
immobilized WT YU2 gp120. Data show proportionally increasing binding responses to immobilized gp120 
at increasing concentrations of 1a. (B) Steady state fit analysis of the Req values for each concentration of 
the Peptide 1 from calculated using the BiaEvaluation software. Error bars represent standard deviation of 
the mean, n = 3. 
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Figure 13.  Dose response of the effects of 1 and 1a on HIV-1BaL pseudovirus antiviral functions.  (A) 
Inhibition of cell infection analyzed using a single round pseudotyped assay.  The IC50 values of 1 and 1a 
inhibit HIV-1BaL infection to the same extent.  (B) Relative p24 release measured using ELISA. The 
calculated EC50 values for 1 and 1a were and 847.2 ± 63 nM and >100,000 nM respectively. The data were 
normalized using untreated virus as a negative control (< 5% p24 release), and p24 release observed with 1% 
triton X treated virus was taken as 100% p24 content.  Sigmoidal curve fits of data were obtained using 
Origin v.8.1 (Origin Lab, Northampton, USA). Error bars represent standard deviation of the mean, n = 3. 
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Table 1. Sequences of peptide triazole thiols, expected and observed mass and length of peptide chain 
between Trp α carbon and SH based on amide bond lengths. *N/A= not applicable due to a capped Cys or 
the absence of a Cys. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Code Designation Sequence Mass (Da) 
Observed 
Mass  
(Da) 
Calculated 
Trp-SH 
Length Å 
1 KR13 RINNIXWS-E-A-M-M-βA-Q-βA-C 2084.73 2085.22 35.96 
1a KR13 dimer RINNIXWS-E-A-M-M-βA-Q-βA-C-Mal 
Peg Mal-C- βA-Q-βA-M-M-A-E-
SWXINNIR 
4694.95 4692.99 N/A 
2 HL01 RINNIXWS-EA-βA-Q-βA-βA-C 1893.66 1893.82 38.99 
3 HL02 RINNIXWS-EA-βA-Q-βA-C 1822.67 1822.82 33.14 
4 HL03 RINNIXWS-EA-βA-Q-C 1751.78 1751.75 26.02 
5 HL04 RINNIXWS-EA-βA-C 1623.70 1623.62 23.23 
6 LB05 RINNIXWS-EA-C 1552.64 1552.54 18.70 
7 LB04 RINNIXWS-E-C 1481.59 1481.46 14.52 
8 LB03 RINNIXWS-C 1352.56 1351.16 10.07 
9 LB02 RINNIXW-C 1265.48 1264.08 5.75 
10 HNG156 RINNIXWS-E-A-M-M 1711.73 1711.49 N/A 
11 KR13b RINNIXWS-E-A-M-M-βA-Q-βA-
C(ACM) 
2155.8 2156.87 N/A 
12 UM15 INNIXW 1006.31 1005.94 N/A 
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 2.2.2 Synthesis and Characterization of PTT Truncates 
 
To determine the optimal linker length between the peptide IXW pharmacophore and the PT-SH, 
we synthesized a family of eight virolytic truncates based on the PTT parent peptide, 1. The PTT 
truncates contained the characteristic peptide triazole pharmacophore, however the C-terminus 
linkers were serially truncated followed by a terminal CysSH (Figure 14).  The effects of the 
truncated linker lengths were determined by analyzing the peptide potencies in antiviral, ELISA 
(CD4 and 17b), SPR, gp120 shedding, and virolysis assays (Table 2).  Peptide 1 served as a positive 
control and 10, a peptide triazole which contains no free thiol group, served as the negative control 
(Figure 11).  The gp120 binding activities were tested by performing competition ELISA assays 
using soluble CD4 (sCD4) and the co-receptor surrogate monoclonal antibody, 17b (Figure 15).  
The gp120 binding ability of these peptides were confirmed by sCD4 competition SPR, with IC50 
values determined for 1-9 (Figure 16A and Table 2).  Both methods displayed that the PTT 
truncates bind gp120 strongly, except the most severely truncated peptide, 9, which displayed 
reduced binding affinity. 
 
Peptide effects on the contents of virus were determined by incubating increasing concentrations 
of peptide with HIV-1BaL virions and quantifying p24 release and gp120 shedding. Similar to the 
gp120 binding analyses, the peptides were relatively active in antiviral inhibition (Figure 16B) and 
all peptides caused gp120 shedding (Figure 17 and Table 2).  In contrast, the peptides with the 
most severe linker truncations were inactive in p24 release assays (Figure 16C).  The non-
sulfhydryl containing peptide, 10, was used as a negative control. 
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Figure 14. Chemical structures of PTTs with serially truncated linker between pharmacophore and C-
terminal Cys.  The pharmacophore sequence, composed of Isoleucine (magenta) - TriazoleProline (blue) - 
Tryptophan (green). The chemical structures were generated in ChemDraw Pro 13.0. 
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Table 2. Binding and Antiviral Properties of Peptide Triazole Thiols. *ND= not determined 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Code Designation ELISA  
IC50 (nM) 
    sCD4        17b 
SPR sCD4 
IC50 (nM) 
Inhibition of 
Infection 
IC50 (nM) 
Gp120 
shedding 
EC50 (nM) 
p24 Release  
EC50 (nM) 
1 KR13 28 ± 4 32 ± 6 93 ± 4 53 ± 19 32 ± 20 1065 ± 40 
2 HL01 110 ± 8 153 ± 14 237 ± 8 143 ± 45 140 ± 37 1800 ± 91 
3 HL02 123 ± 51 142 ± 25 153 ± 47 114 ± 40 ND 1321 ± 26 
4 HL03 199 ± 23 198 ± 35 172 ± 66 197 ± 38 183 ± 37.9 2202 ± 61 
5 HL04 183 ± 13 227 ± 30 ND 286 ± 13 ND 4762 ± 73 
6 LB05 207 ± 29 195 ± 41 ND 469 ± 19 ND 26730 ± 82 
7 LB04 218 ± 10 713 ± 144 344 ± 70 554 ± 7 288 ± 133 33210 ± 89 
8 LB03 331 ± 11 939 ± 186 379 ± 16 550 ± 63 523 ± 97.6 38420 ± 49 
9 LB02 589 ± 74 906 ± 128 2913 ± 
798.8 
7030 ± 2200 9366 ± 563 >> 500000 
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Figure 15. ELISA Competition of gp120 by PT thiol truncates.  Sandwich ELISA was used to determine the 
extent of (A) 17b and (B) CD4 antagonism caused by largely truncated peptide triazole thiols. The data 
display that serially truncated PTT’s retain gp120 binding affinity as the distance between the IXW 
pharmacophore and sulfhydryl group is shortened.   Reduced gp120 binding affinity of 9 is due to complete 
elimination of the linker.  IC50 values were determined by fitting the peptide data to logistic function in Origin 
(OriginLab) and are listed in Table 1. Error bars represent standard deviation of the mean, n = 3. 
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Figure 16. (A) Binding activity of peptide triazole thiols as determined by surface plasmon resonance CD4 
Competition.  Data points for response at steady state were extracted from sensorgrams and fit to a four-point 
parameter sigmoidal equation resulting in IC50 values listed in Table 1.  (B) Dose response of the effects of 
peptide triazole thiol truncates on HIV-1BaL pseudovirus cell infection.  Inhibition of cell infection was 
analyzed using a single round pseudotyped assay.  The IC50 values are reported in Table 1.  The data show 
that serially truncated PTT’s progressively lose antiviral potency as the distance between the IXW 
pharmacophore and sulfhydryl group is shortened.  (C) p24 release from HIV-1BaL pseudotyped virus caused 
by PTT’s.  Relative p24 release was measured using ELISA.  The data were normalized using untreated virus 
as a negative control (< 5% p24 release), and p24 release observed with 1% triton X treated virus was taken 
as 100% p24 content. Sigmoidal curve fits of data were obtained using Origin v.8.1 (Origin Lab, 
Northampton, USA).  Error bars represent standard deviation of the mean, n = 3. 
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Figure 17. Gp120 shedding of virolytic peptides.  Relative gp120 shedding was performed by western blot 
analysis (see Methods section).  Bands of gp120 protein detected by chemiluminesence on film were 
quantified by Image J analysis.  EC50 values obtained are in Table 2.  The data were normalized by using 
untreated virus as a negative control (< 5% shedding) and 1% triton X treated virus was taken as 100% gp120 
shedding. 
 
 
 
 
 
 
 
 
2.2.3 Analysis of the Effect of PTT Linker Length on p24 Release 
 
Using the serially truncated peptide triazole thiols, we compared the p24 release and antiviral 
activities, then assessed this relationship by analyzing the p24 release vs. binding-dependent 
properties as a function of the length of the linker between the IXW pharmacophore and SH group.  
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The results in Table 3 show that the progressive truncation of the C-terminal linker suppresses the 
virolytic efficiency of PTTs (Figure 18). 
 
 We observed a discontinuous relationship between the length of the C terminus linker and p24 
release.  The proportionately greater effect of linker shortening on virolysis versus antiviral potency 
argues that a minimal length is required for efficient virolysis.  It is well known that HIV-1 contains 
ten conserved disulfides’, nine of them are located in gp120 and one in gp41.  Observation of a 
minimum linker length between the peptide triazole pharmacophore and peptide triazole SH for 
p24 release supports the hypothesis that the virolytic effect of peptide triazole thiols is promoted 
by a disulfide exchange between the peptide C-terminal thiol group and a specific disulfide in 
gp120. 
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Table 3. Calculated Correlations between Virolysis and Binding of Peptide Triazole Thiols. 
 *ND= not determined. 
 
 
 
 
 
 
Code Designation p24 EC50/ 
ELISA IC50 
 
 
sCD4         17b 
p24 EC50/ 
Inhibition 
of 
Infection  
IC50 
 
p24 EC50/ 
gp120 
Shedding  
 
EC50 
p24 EC50/  
SPR sCD4  
 
 
IC50 
1 KR13 38.0 33.3 20.1 3.3 11.5 
2 HL01 16.4 11.8 12.6 12.9 7.6 
3 HL02 10.7 9.3 11.6 ND 8.6 
4 HL03 11.1 11.1 11.2 12 12.8 
5 HL04 26.0 20.9 16.6 ND ND 
6 LB05 128.9 136.9 56.9 ND ND 
7 LB04 152.3 46.5 59.9 115.3 96.5 
8 LB03 116.0 40.9 69.8 73.5 101.3 
9 LB02 >>848.8 >>551.8 >> 71.1 >> 53.4 >> 171.6 
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Figure 18.  (A) Relative p24 release vs. length (based on cell infection inhibition) (B) Relative p24 release 
vs. length (based on ELISA).  (C) Relative p24 Release vs. Length (based on SPR CD4 competition).  (D) 
Relative p24 release vs. length (based on gp120 Shedding).  Truncated peptide triazole thiols lose virolytic 
potency as the distance shortens between the thiol group and Trp residue of the IXW pharmacophore. 
 
\ 
 
 
 
2.2.4 PTT Docking onto gp120 using Molecular Dynamics (MD) Simulation 
 
We sought to identify possible sites of disulfide exchange within gp120 by determining the 
trajectory of the peptide SH group. Unfortunately, we do not have a crystal structure of a peptide 
triazole bound to gp120. Therefore, we performed a MD simulation and enhanced docking of PTT, 
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peptide 8, to gp120 to identify nearby disulfide residues that may interact with the peptide 
sulfhydryl group (Figure 19). Modeling studies performed by Dr. Adel Rashad show there are 
several conserved disulfide bonds surrounding the CD4 binding pocket, which may be involved 
in the virolytic mechanism. We postulate that these residues participate in disulfide exchange with 
the sulfhydryl group of PTTs, a process which is known to be required for entry of several 
enveloped viruses87.  
 
 
 
 
 
 
 
Figure 19.  Molecular docking simulation of PTT, 8, in complex with gp120.  The structure of 8 (carbons 
shown in cyan) was docked onto gp120 resulting in the binding model shown. Peptide 8 binds in a site 
overlapping the CD4 pocket (surface shown in grey), with the C-terminal Cys (SH shown as CPK) trajectory 
to the conserved disulfide cluster (blue; C296-C331, yellow; C385-C418, violet; C378-C445, orange; C119-
C205) which encompasses possible sites of disulfide interaction. The model shows that the peptide SH group 
is well solvated and with the conformational flexibility can reach any of the disulfide bridges shown. 
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From prior molecular dynamics simulated model of peptide triazole-gp120 binding, it was shown 
that the hydrophobic motif (IXW) of peptide triazoles binds to specific residues that are buried 
within the CD4 binding cavity of gp12088. However, past modeling for peptide triazoles utilized 
phenyl-containing scaffolds instead of the ferrocenyl appendage found in high affinity peptide 
triazole thiols. The use of the phenyl substituent enabled the use of CHARMM, which possessed 
surface desolvation and energy parameters for a phenyl moiety and not those for ferrocene rings.  
The new, enhanced docking model (Figure 19)  now displays the PT thiol truncate, 8, which 
contains the ferrocenyl apppendage native to PT’s, in complex with the core gp120. Molecular 
docking is most accurate when using small, rigid molecules. Because peptides are large and 
flexible, we performed these studies with the smallest PTT that was still capable of causing p24 
release, 8. The molecular docking model of 8 bound to gp120 predicted that pharmacophore binds 
in a site overlapping the CD4 binding site, which was also observed in the previous MD model88.  
Furthermore, the C-terminus of the PT was shown to project towards the CD4 exposed disulfide 
cluster in the variable loop of gp120 (Figure 19).  From our model of PTT docked onto gp120, 
we speculate that PTTs interact with the CD4-exposed disulfide cluster in gp120, composed of 
C296-C331 (V3 loop) disulfide, C385-C418 (C4) disulfide, and C378-C445 (C3) disulfide.   
 
 
2.2.5 gp120 Protein Ligands Used to Deduce Likely Disulfides Targeted 
 
To probe the disulfide-containing gp120 region that is the contact site for the PT-SH group, we 
performed virolysis competition assays with several gp120 neutralizing antibodies (Figure 20 and 
21).  It is well known that the V3 loop of gp120 is necessary for proper folding conformation of 
mature Env, for this reason we initiated an investigation to determine if these disulfides are 
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involved in p24 release caused by PTTs89,90.  We performed competition assays with 2G12, a 
broadly neutralizing conformational antibody of HIV-1.  2G12 has previously been shown to bind 
to the mannose rich epitope at the base of the gp120 V3 loop91, where it binds to the glycans 
associated with N295, N332, and N392.  Additional glycans that influence 2G12 binding are the 
mannose residues linked to N339 and N386. In all, these 2G12 binding-glycans occupy the same 
V3 loop region as the CD4 exposed disulfide cluster.   The 2G12 p24 assays were performed with 
the control peptide, 1, the longest of the truncated virolytic peptides, 2, and the short linker truncate 
which still causes p24 release, 8.   These inhibition assays displayed that 2G12 inhibits the ability 
of all three virolytic peptides to cause p24 release (Figure 21A). To address the possibility that 
2G12 may inhibit six helix bundle formation we performed an infection assay where pre-chilled 
virus was added to cells while keeping cells at 4 °C and incubated for four hours to allow 
commitment of receptor binding to gp120 but to arrest the process in the pre-fusion step, preventing 
six-helix bundle formation. Then, after washing to remove unbound virus and adding serial 
dilutions of 2G12, we raised the temperature to 37 °C and carried out the assay accordingly as 
described in Methods section. We added 10 µM of T20 at the same time as 2G12, as a negative 
control to demonstrate that 6-helix bundle formation had not occurred at the time of 2G12 addition.  
This was verified by the complete inhibition observed, whereas the 2G12 treated cells showed no 
infection inhibition, verifying that 2G12 does not prevent six-helix bundle formation through direct 
interaction (Appendix Figure 32).  These results suggest that the 2G12 antibody, which binds to 
glycans at the base of the V3 loop, effectively inhibits p24 release induced by virolytic peptides.   
 
To confirm the specificity of 2G12 binding to the V3 loop glycosyl, we sought to perform this assay 
with a different protein which is also known to bind to glycans of HIV-1, yet in a location different 
from that of 2G12.  Therefore, we chose to perform a p24 release assay with Cyanovirin, a protein 
produced from cyanobacterium Nostoc ellipsosporum and known to have antiviral activity against 
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several viruses92,93.   Cyanovirin virucidal activity is caused by high affinity interactions with gp120 
and specifically to high mannose residues found on the outer domain of HIV-1 Env92. Previously, 
we showed that Cyanovirin does not compete with peptide triazole binding. Here, we aimed to 
determine its’ effect on PTT-induced p24 release.  Our data displayed that Cyanovirin does not 
inhibit p24 release of virolytic peptide triazoles, 1, 2, or 8 (Figure 21B).   
As mentioned above, there are several disulfides clustered around the V3 loop, however another 
possible site of disulfide exchange is located in the V1/V2 loop.  The disulfide C119-C205 links 
the V1 and V2 loop and is also important for aiding in V3 loop access to the CD4 exposed 
conformation82.  Further, our flexible docking suggested that the terminal Cys of PTT’s could 
potentially extend past to the C119-C205 disulfide.  For this reason, we aimed to determine the 
effect of the gp120 epitope antibody, 697-30D, on virolysis caused by peptide triazole thiols. The 
neutralizing antibody, 697-30D, is specific for the V2 region of gp120 and recognizes the epitope 
that spans the region 164-19482.  The results of a p24 release inhibition assay showed that the 
conformational antibody 697-30D did not affect the ability of peptide triazole thiols to disrupt HIV-
1 virions as shown in Figure 21C.  In all, these data implicate the CD4 exposed disulfide cluster 
of the V3 loop as a possible contact site of PT-SH involved in the mechanism of PTT-induced 
virolysis.   
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Figure 20.  Cartoon of bound Gp120 Ligands in relation to possible disulfides involved in PTT “thiol-
exchange”.   Sticks depiction of KR13 (navy blue) bound to the CD4 conformation of gp120 (red ribbon). 
2G12 (red 6 point star) binds to asparagine-linked glycans located at the base of the V3 loop. Cyanovirin 
(orange 4 point star) binds to several mannose residues surrounding the outer domain. 697-30D (green circle) 
binds in the V1/V2 loop. Disulfide linkages C378-C445 (C3) shown in green, C385-C415 (C4) shown in 
yellow, C296-C331 (V3) shown in cyan, and C119-C205 (V1/V2) in magenta. 
 
 
 
 
 
 
 
57 
 
 
 
 
 
Figure 21. Effect of protein ligands on p24 release by PTTs.  (A) Effect of conformational antibody 2G12 
on p24 release.  HIV-1BaL pseudovirus was treated in the presence and absence of 10 µM 1, 14 µM 2, 50 µM 
8 and serial dilution of 2G12 starting at 10 nM. (B)  Effect of carbohydrate binding protein, Cyanovirin, on 
p24 release.  HIV-1BaL pseudovirus was treated in the presence and absence of the respective EC80 
concentrations of 1, 2, and 8 and serial dilution of Cyanovirin starting at 1 µM. (C) Effect of conformational 
antibody, 697-30D, on p24 release.  HIV-1BaL pseudovirus was treated in the presence and absence of 10 µM 
1, 14 µM 2, 50 µM 8 and serial dilution of 697-30D starting at 1 µM. (D) Effect of 2G12 on 1 binding to 
gp120. 17b Sandwich ELISA assay was performed with constant concentration of 2G12(2.5 µg/mL) and 
serial dilutions of 1. 
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2.3 DISCUSSION 
 
Previously, we reported a sub-class of peptide triazole inhibitors, which contain C- terminal 
sulfhydryl groups and irreversibly disrupt HIV-1 virions, evidenced by capsid p24 release94.  Since 
the role of the thiol was implicated in the virolytic breakdown of Env, in a more recent study, we 
characterized a sulfhydryl blocked variant of 1, (11, KR13b) 70.  11 potently inhibited HIV-1 
infection, but did not cause the release of protein capsid p24.  These findings led us to characterize 
the mechanistic effects of the peptide triazole thiol, 1, which was shown to cause gp120 shedding 
and p24 release.  Furthermore, these molecular effects of 1 were examined in virolytic breadth 
studies using HIV-1 clades A, B, and C.  Virolytic breadth studies displayed dose dependent p24 
release, thereby confirming a conserved mechanism of action induced by peptide triazole thiols70. 
The ability of peptide triazole thiols to cause virolysis led to many questions concerning the role of 
the C-terminal thiol and the mechanism of virolysis induced by these peptides. In the current study, 
we initiated an inquiry of the structure - activity relationship of virolytic peptide triazoles by 
identifying the role of the thiol group and its mode of action once it encounters HIV-1 Env. 
We started by reconfirming the role of the sulfhydryl by synthesizing an obligate dimer of (1a, 
KR13) a variant in which two molecules of 1 were linked on opposing sides of a bismaleimide, 
blocking both peptide Cys residues. We aimed to eliminate completely the possibility that viral 
membrane disruption may be an effect of peptide 1 self-dimerization, subsequently allowing each 
1 monomer to potentially bind to two separate Env spikes simultaneously and stressing the viral 
membrane. From our data, we observed that KR13 dimer was a potent inhibitor of HIV-1 infection, 
however it was not lytically active (Figure 14).  The inability of 1a to disrupt viral particles ruled 
out the possibility that viral lysis was an artifact of peptide 1 self-dimerization. Instead, the results 
confirm that a free sulfhydryl group is indeed a requirement for peptide triazole thiol activated 
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virolysis. These results argue that there is a direct role of the free SH, possibly by exchange with 
disulfides of gp120. 
 
We argued that if disulfide exchange occurs between the PT SH group and the gp120 disulfide 
cluster proximal to the CD4 binding site, then there must be a minimal length of C-terminal linker 
needed for the Cys-SH to contact the disulfides for efficient virolysis.  Therefore, we speculated 
that decreasing the length of the peptide triazole thiol linker would suppress lysis but proportionally 
retain binding affinity, antiviral potency and gp120 shedding activity, all of which are caused by 
active core binding but not the free SH.  To test this prediction, we synthesized and characterized 
a library of truncated peptide triazole thiols, based on the parent peptide 1 binding core structure, 
with serially truncated linker lengths at the C- terminal end.  We found that once the C-terminus 
linker is reduced to less than 20 Å (Table 1) we observe a disproportionate loss of virolysis versus 
antiviral activity.  This suggests that there is a minimal required spacing, between the peptide 
triazole pharmacophore and thiol group of 20 Å, which is necessary for virolysis.  We found that 
even the most shortened peptides retain gp120 binding affinity and inhibit viral replication, 
however they do not possess the added feature of virolysis. Figure 17 displays that the PTT library 
of peptides all potently bind HIV-1 at similar extents as, observed by cell infection and SPR CD4 
competition assays. This is likely attributed to the active site pharmacophore (IXW), which is 
maintained in all peptide triazoles and has a strong binding affinity to the residues within the CD4 
binding site. However, the virolysis assays strikingly display a distinct group of inhibitors which 
are potent virucides and another distinct group of inhibitors which do not have lytic capabilities.  
The data argues that the PT-SH may contact specific disulfides, and the inability to reach Env 
gp120 disulfides contributes to loss of the effect of viral lysis. 
HIV-1 Env consists of ten conserved disulfides and of these disulfides the transmembrane protein, 
gp41, contains one, while gp120 contains the other nine disulfides.  Disulfide linkages C378-C445 
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(C3), C385-C415 (C4), C296-C331 (V3), and C119-C205 (V1/V2) are of particular interest 
because they are found near the CD4 binding site, also the region of virolytic peptide triazole 
binding.  For this reason, they are potential sites of “thiol exchange”.  To investigate the possible 
interaction of the PT thiol group with the disulfide cluster surrounding the CD4 binding site, we 
docked a PTT truncate to an F105- bound gp120 conformation and examined this spatial 
relationship.  The docking study was in agreement with a previous MD simulation of PT’s, which 
suggested that the IXW tripartite motif binds to residues lining the Phe43 cavity88. Additionally, 
the docking model showed that the C terminus linker and SH of the peptide do not project past 
gp120’s V1/V2 region, yet it extends toward the disulfide linkages in the C3, C4, and V3 domains 
of gp120.  In all, the molecular docking study confirmed the specificity of PT-gp120 binding, yet 
several possible disulfide candidates still remained.  
We continued our SAR studies by using epitope specific protein ligands to map the trajectory of 
sulfhydryl contact with gp120 in viral lysis.  2G12, an antibody which binds to the base of the 
gp120 V3 loop, reduced the ability of virolytic peptides to cause p24 release in virolytic inhibition 
assays (Figure 21A).  The data also show that the 2G12 antibody inhibited p24 release of peptide 
1 with an IC50 of 45 ± 5.6 pM and similarly inhibited peptide truncates. 2G12 suppression of the 
release of capsid protein p24 of several PTT’s of distinct lengths strongly indicates that PTT’s exert 
their mechanism by interacting with a common contact site and that the contact site is near the V3 
loop.  This possibility was supported by finding that there was no inhibition of p24 release when 
viral particles were treated with the lectin Cyanovirin or antibody 697-30D (Figures 21B and C), 
therefore validating the importance of the V3 loop disulfides.  Disturbance of this V3 loop disulfide 
has been found to be detrimental to gp120 folding, CD4 binding, and infectivity, thus is it not 
surprising that disulfide exchange in this region could cause complete loss of membrane integrity.  
Further support for the role of the V3 loop disulfide cluster in lysis was attributed by our molecular 
docking simulation of peptide 8 bound to gp120 (Figure 20), which showed that the trajectory of 
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the SH group extends toward the cluster of disulfides.  Although the simulation cannot precisely 
extrapolate the PTT thiol contact with a specific disulfide, taken together with the epitope mapping, 
it can be inferred that the V3 loop disulfide cluster has a pertinent role in the activation of Env lysis 
induced by PTT’s. 
Peptide triazole thiols are novel virucides due to their specificity, inhibition potency, and ability to 
cause gp120 shedding. Additionally, PTT-induced viral inactivation results in residual antigenic 
virions, making them potential therapeutics.  For this reason, minimized virolytic peptides could 
be used as drug leads, upon refining the pharmacophore by medicinal chemistry, prevention and 
therapeutic approaches to suppress the progression and transmission of AIDS and treating HIV-1 
infected patients.   
 
 
 
 
 
 
 
 
 
 
 
 
 
62 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3: Mechanism of Peptide Triazole Thiols Induced Virolysis by 
Mimicking HIV-1 Fusion Machinery 
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3.  Introduction 
 
 
In Chapter 2, I described experiments that provide evidence that peptide triazoles, specifically those 
with C-terminal Cys residues, are implicated in disrupting viral membrane integrity by disulfide 
bond interference. Based on those studies I investigated the hypothesis that the disruption leads to 
disulfide exchange in Env and the specific disulfide residues of the Env proteins in this process. I 
further sought to correlate the thiol/disulfide reaction properties in lysis with those reported to occur 
during virus cell infection. 
 
 
3.1 MATERIALS AND METHODS  
 
3.1.1 Reagents 
 
Escherichia coli strain XL-10 gold (Agilent) and Stbl2 cells (Invitrogen) were products of Novagen 
Inc. (Madison, WI). Thermostable DNA polymerase (pfu ultra™) was obtained from Stratagene 
Inc (La Jolla, CA). Custom-oligonucleotide primers were supplied by Integrated DNA technologies 
(IDT). DNA plasmids encoding HIV-1BaL Env (catalog # 11445) and NL4-3 R- E- Luc+ were 
obtained from the NIH AIDS Reagent Program, Division of AIDS, NIAID and were a kind gift of 
Dr. J Mascola and Dr. N Landau respectively.  All other reagents used were of the highest analytical 
grade available. 
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3.1.2 Peptide Synthesis and Click Conjugation  
 
All sequences and denotations of peptides reported are given in Table 1.  Peptides were synthesized 
manually by stepwise solid-phase peptide synthesis (SPPS) and purified as described in Chapter 2. 
Bt-KR13 was synthesized and purified by SciLight peptide. 
 
3.1.3 Viral Inhibition Assays 
The luciferase activity for the infection assay was performed as described in Chapter 2. All 
experiments were performed at least in triplicate, and results were expressed as relative infection 
with respect to cells infected with virus in the absence of inhibitor (100% infected). 
 
 
3.1.4 Sulfhydryl Reagent “Treat/Wash” Viral Infection Assays 
 
Modified human osteosarcoma cells engineered to express CD4 and CCR5 (HOS.T4.R5), as well 
as the vector for pNL4–3.Luc+ R- E-, were obtained through the NIH AIDS Repository from Dr. 
Nathaniel Landau, while the vector expressing the CCR5-targeting spike protein BaL.01 gp160 
was obtained through the NIH AIDS Repository from Dr. John Mascola.  The recombinant virus 
was produced as previously explained. The viral stocks were first incubated with serial dilutions of 
Dithiothreitol (DTT), Iodoacetamide (IAAm), and (tris(2-carboxyethyl)phosphine) (TCEP) at 37 
°C for 30 min, then transferred to 30 kDa centrifuge filters (Amicon) and spun at 2000 x g at 37° 
C for 7 min.  After the 7 min spin, 165 µL of 1 x PBS was added to the samples and mixed 
thoroughly via pipetting.  The centrifugation and PBS wash were repeated 3 times; at this point, 
the treated virus was added to 96 well tissue culture plates, with HOS.T4.R5 cells, pre-seeded for 
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24 hrs at 8,000 cells per well.  After 48 hours infection, with a growth medium wash step 24 hours 
post-treatment, the cells were lysed with passive lysis buffer (Promega) followed by 3 freeze–thaw 
cycles.  Luciferase assays were performed using 1 mM d-Luciferin salt (AnaSpec) as substrate and 
detected on a 1450 Microbeta liquid scintillation and luminescence counter (Wallac and Jet).  The 
single-round, pseudoviral infection luciferase reporter assay was conducted as previously 
described69.  Nonlinear regression analysis was performed using Origin v.8.1 (OriginLab, 
Northampton, USA) to calculate the IC50 values.  All experiments were performed at least in 
triplicate, and results were expressed as relative infection with respect to cells infected with virus 
in the absence of inhibitor (100% infected). 
 
3.1.5 Optical Biosensor Binding Assays 
 
Surface Plasmon Resonance (SPR) kinetic interaction experiments were performed and analyzed 
as explained in Chapter 2.  
 
 
3.1.6 Virolysis Assays 
 
The ability of the peptide triazole thiols to cause virolysis of pseudotyped HIV-1BaL virus was 
analyzed by quantifying p24 release as explained in Chapter 2.   
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3.1.7 Assays for Sulfhydryl Reagent Inhibition of Virolysis 
 
1mM DTT and TCEP and 0.02 mM IAAm were incubated with a 1:4 working dilution of purified 
pseudotyped HIV-1BaL virions for 30 min at 37 ºC. Reagents were removed from virions by 
centrifugation at 2000 x g for 7 min at 37 °C in 30 kDa centrifugation filters (Amicon). The retained 
HIV-1BaL virions were washed with 165 µL PBS, and this was repeated three times. The virus 
particles were then treated with serial dilutions of 1, 11, and 12 for 30 min at 37 ºC. The soluble 
fraction was separated, and the extent of p24 release was determined by the same protocol as the 
sandwich ELISA protocol described above.  Virus in PBS was the negative control, while virus in 
1% Triton-X 100 was the positive control.  Quantified values from triplicate assays were plotted as 
a function of p24 released compared to the positive control.  These values were fit using Origin 
v.8.1 (Origin Lab, Northampton, USA) to determine EC50 values. 
 
 
3.1.8 Western Blot Analysis of Biotinylated PTT Interaction with gp120 and HIV-1BaL 
 
For western blot detection of peptide triazole effects on gp120 protein, 5 µM of peptide triazoles 
Bt-KR13, Bt-KR13b, KR13, and KR13b were stirred and incubated with 100 nM soluble HIV-1Yu2 
gp120 at 37 °C for 4 hrs.  After the 4 hr incubation, non-reducing western blot analysis was 
performed by adding 15 µL of reaction samples to 15 µL of 1x Laemmli buffer.  Biotinylated 
Bovine Serum Albumin (Thermo Scientific), 5 and 20 nM, was used for biotin controls. Reducing 
western blot analysis was performed by adding 15 µL of reaction samples to 15 µL of 1x Laemmli 
buffer in 5% β-mercaptoethanol.  Gp120 was detected with 1:3000 dilution of anti-gp120 D7324 
(Aalto) and anti-sheep IgG conjugated HRP (Life Technologies) and biotin was detected by 1:3000 
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dilution of mouse anti-biotin (Jackson Immuno Research Labs, Inc) and anti-mouse IgG conjugated 
HRP (Dako).  For western blot detection of peptide triazole effects on pseudotyped HIV-1BaL, a 1:2 
working dilution of purified HIV-1BaL virions was incubated and stirred with 5 µM of peptide 
triazoles Bt-KR13, Bt-KR13b, KR13, and KR13b at 37 °C for 4 hrs. Gp120 and biotin detection 
were performed as mentioned above.  A standard curve using monomeric HIV-1YU2 gp120 serially 
diluted (1:2, v/v) starting at 100 ng/ml was used to determine the working dilution of pseudotyped 
HIV-1BaL. 
 
3.1.9 Design and construction of various HIV-1BaL Env mutants   
 
Wild-type (WT) HIV-1BaL Env construct in a pcDNA3.1D vector (NIH AIDS reagent program). 
This construct was used to prepare HIV-1BaL Env substitution mutants. Mutants of HIV-1BaL Env 
were created using Quick-change site-directed mutagenesis reagents and methods (Stratagene). The 
primers used for mutagenesis were custom synthesized at IDT DNA. The following forward 
primers and their reverse complements were used in the 5′-3′ direction:  
C598A Forward: 5’ - ggg gat ttg ggg tgc ctc tgg aaa act c  
C598A-Reverse: 5’ - gag ttt tcc aga ggc acc cca aat ccc c 
C604A Forward: 5’ - gga aaa ctc atc gcc acc act gcc g  
C604A Reverse:  5’ - cgg cag tgg tgg cga tga gtt ttc c 
C385V Forward: 5’ - ggg aat ttt tct acg cta att caa cac aac tg  
C385V Reverse:  5’ - cag ttg tgt tga att agc gta gaa aaa ttc cc 
C415S Forward: 5’ - cac aat cac act ccc agc cag aat aaa ac  
C415S Reverse:  5’ - cac aat cac act ccc agc cag aat aaa ac   
C378S Forward: 5’ - gtg acg cac agt ttt aat agt gga ggg gaa  
C378S Reverse: 5’ - cac tgc gtg tca aaa tta tca cct ccc ctt    
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C445S Forward: 5’ - ccc atc aga gga caa att aga agt tca tca aa  
C445S Reverse:  5’ - ggg tag cct gtt taa tct tca agt agt tt 
C296E Forward: 5’ - gaa tct gta gaa att aat gag aca aga ccc aac aac 
C296E Reverse:  5’ - gtt gtt ggg tct tgt ctc att aat ttc tac aga ttc   
C331K Forward: 5’ - ata aga caa gca cat aag aac ctt agt aga gca 
C331K Reverse: 5’ - tgc tct act aag gtt ctt atg tgc ttg tct tat 
 
 
Mutagenesis was confirmed by sequencing (Genewiz Inc.) using the BGHR primer or custom-
made primers that span the Env cassette (IDT).   
 
3.1.10 Mutant HIV-1BaL Binding to CD4 and 17b ELISA 
 
The ability of the HIV-1BaL mutants C296-C331, C378-C445, C385-C415, and C598A-C604A to 
bind sCD4 and mAb 17 was analyzed by ELISA72. Gradient-purified viruses were added to a 100 
kDa concentrator (Amicon) followed by centrifugation at 2,000 x g at 4 °C for 3 minutes on a 
tabletop 5424R centrifuge (Eppendorf). The retained HIV-1BaL virions were washed with 250 µL 1 
× PBS.  The wash step was repeated three times and the flow through was discarded. 100 µL of 
concentrated and washed virus was added to 100 µL fixative mixture comprised of 0.2% 
Glutaraldehyde in 2% Paraformaldehyde.  The mixture was incubated at 4 °C for 15 min followed 
by the addition of 100 µL 0.1 M Glycine followed by another incubation at 4 °C for 15 min to 
quench the reaction.  HIV-1BaL virus-fixative sample was added back to 100 kDa concentrators 
(Amicon) and spun at 2,000 x g for 3 minutes at 4 °C to perform a buffer exchange with 1 × PBS.  
HIV-1BaL was adsorbed at 50 µL per well to a 96-well high binding polystyrene ELISA plate 
(Corning) for 12 hrs at 4 °C with gentle rocking. The HIV-1BaL was then removed from the plate 
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and the latter was blocked with 200 μL/well of 3% BSA (Research Products International, Corp) 
in 1× PBS for 2 hrs at 25 °C, followed by a plate washing step with 1× PBS-T.  For the CD4 binding 
experiments, 50 μL/well of 30 nM sCD4 in 0.5 % BSA dissolved in 1x PBS was added to the plate 
and incubated for 1 hr at 25 °C. This and all subsequent incubation steps were done in 0.5% BSA 
in PBS.  After a 1 hour incubation period, the plate was washed 3 times with PBS-T followed by 
addition of 100 μL/well of biotinylated anti-CD4 (OKT4) antibody (eBioscience) at a 1:5000 
dilution and the plate incubated for an additional 1 hr at 25 °C.  After plate washing, streptavidin-
bound HRP (AnaSpec) was added at a 1:5000 dilution and again incubated for 1 hr at room 
temperature.  For the 17b binding experiments, 50 μL of 15 nM mAb 17b was added to the plate-
immobilized HIV-1BaL. After a 1 hr incubation at 25 °C, the plate was washed 3 times with PBS-T, 
followed by the addition of a horse radish peroxidase (HRP)-conjugated goat anti-human antibody 
(CHEMICON) which was incubated for 1 hour at room temperature.  The extent of HRP conjugate 
binding was detected colorimetrically in both assays by adding 200 μL/well of 0.4 mg/ml of o-
phenylenediamine dihydrochloride (OPD) (Sigma-Aldrich) dissolved in Sodium Citrate with 
Perborate (Sigma-Aldrich) for 30 min in the dark.   Capsid p24 was quantified on a separate plate 
using the concentrated virus collected after the quenching step.  Quantification was done using 
1:5000 dilutions of anti-rabbit p24 (Abcam) and then anti-rabbit IgG fused to horseradish 
peroxidase (HRP) (Invitrogen).  Gp120 was quantified using the same virus after the quenching 
step by western blot analysis with 1:5000 dilution of anti-gp120 D7324 (Aalto) and anti-sheep IgG 
conjugated HRP (Life Technologies). The western blots were quantified using Image J software. 
Plates were read at 450 nm using a microplate reader (Molecular Devices).  The optical density 
(OD) units generated from either CD4 or 17b binding to the pseudovirus samples were normalized 
based on the p24 content of each mutant and the gp120 content determined by Western blot to allow 
for comparison between the mutants.  Each experiment for CD4 or 17b binding contained a 
standard curve using sCD4 and 17b binding to monomeric HIV-1YU2 gp120 serially diluted (1:2, 
v/v) starting at 100 ng/ml. 
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3.1.11 Origin Pro. 8 curve fitting of dose dependence data 
 
Data analysis of dose-dependence measurements performed in this study was conducted by 
sigmoidal curve fitting using the Origin v.8.1 (Origin Lab, Northampton, USA) software as 
explained in Chapter 2.   
 
3.2 RESULTS 
 
3.2.1 The Effect of sulfhydryl reagents on p24 release by KR13 
 
Previous work has shown that cysteine reduction and alkylation impairs the ability of HIV-1 to 
bind CD495, thereby suggesting that the conserved disulfides are critical to the function of the virus 
and may play a role in the infection process96,97. Due to the close proximity of the PTT thiol to 
disulfides and the requirement of a free SH for lysis, we examined the role of disulfide exchange 
within gp120 by using sulfhydryl blockers and reducers to analyze their effects on p24 release 
induced by 1.  The sulfhydryl blocker, Iodoacetamide (IAAm), is an irreversible alkylating reagent, 
known for its ability to bind free sulfhydryls.   We also evaluated the effect of Dithiothreitol (DTT), 
a reducing agent which undergoes two sequential disulfide-exchange reactions when reducing the 
typical disulfide bond,98 and the irreversible non-thiol reducing agent, tris(2-
carboxyethyl)phosphine (TCEP).  Prior to assessing the effect of these reagents on PTT-induced 
virolysis, we determined their effects on HIV-1 virions.  In agreement with previous findings, these 
sulfhydryl blocking and reducing reagents were found to inhibit HIV infection95.  However, we 
showed that the viral infectivity was regained after pre-treatment and wash removal of reagents 
(“treat/wash”) before assays (Figure 22A).  
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Figure 22. Effect of sulfhydryl reagents on PTT induced p24 release.  (A) Effect of Sulfhydryl reagents on 
HIV-1BaL infectivity. DTT, TCEP and IAAm treated HIV-1BaL virions added to HOS cells to test infectivity.  
(B) Effect of HIV-1BaL treatment and removal of DTT, followed by 1 treatment and p24 release analysis (C) 
Effect of HIV-1BaL treatment and removal of TCEP, followed by 1 treatment and p24 release analysis. (D) 
Effect of HIV-1BaL treatment of DTT serial dilutions and removal with subsequent treatment of 0.02mM 
IAAm. Followed by 1 treatment and p24 release analysis. 
 
 
 
 
 Additionally, these reagents did not cause p24 release. Therefore, we performed virolysis assays 
in which the virions were exposed to DTT, TCEP, or IAAm, in the “treat/wash” protocol before 
p24 analysis with 1. Interestingly, DTT and TCEP pre-treatment of pseudotyped HIV-1BaL caused 
72 
 
greater sensitivity to peptide 1-induced p24 release (Figures 22B and C).  Additionally, we showed 
that the enhanced p24 release potency caused by reducing agent pre-treatment was specific to thiol 
containing peptides (Figure 23). 
 
 
 
 
 
 
Figure 23.  Peptide Triazole Specificity of DTT-induced enhancement of HIV-1BaL.  Effect of DTT treated 
HIV-1BaL was compared with 1 and non-thiol containing peptides, 11 and 12 and analyzed for p24 release. 
Error bars represent standard deviation of the mean, n = 3. 
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Furthermore, we showed that virions exposed to DTT and subsequent IAAm, “treat/wash” after 
each reagent, were not capable of causing p24 release when treated with KR13 (Figure 22D).   The 
enhanced lytic potency of 1 on DTT treated virions in comparison to untreated virions suggest that 
disulfide reduction in the HIV-1 Env protein augments the efficiency of peptide triazole thiol lysis 
activity.  These data argue that PTTs cause virolysis by reducing disulfides and the free sulfhydryl 
group initiates a cascade of disulfide exchange reactions leading to virolysis. 
 
 
 
3.2.2 Functional Properties of Biotinylated KR13 
 
Based on the current hypothesis that PTT’s cause p24 release by propagating disulfide exchange, 
we postulated that the PTT C-terminal thiol group covalently binds to a free gp120 cysteine or 
interacts with a cysteine of a disulfide pair, leading to HIV-1 viral lysis.  To test this, we synthesized 
a peptide 1 derivative that contained a Lys (Biotinyl) residue at the N-terminus, denoted Bt-KR13 
(Figure 24A) as well as a biotinylated control peptide derived from 11, denoted Bt-KR13b. Bt-
KR13b also contained a Lys (Biotinyl) residue at the N-terminus as well as an Acetamidomethyl 
(Acm) capped cysteine residue at the C-terminus (Figure 24B). We assessed the functionality of 
Bt-KR13 and Bt-KR13b with their respective parent peptides, 1 and 11, for gp120 binding, HIV-1 
infectivity and p24 release.   
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Figure 24. Chemical Structure of Biotinylated PTTs. (A) Bt-KR13 is the biotinylated variant of 1 (KR13) 
containing a biotinyl (Lysine) amino acid at the N-terminus. (B) Bt-KR13b is the biotinylated variant of 11 
(KR13b) containing a biotinyl (Lysine) amino acid at the N-terminus and Cys(Acm) at the C-terminus. 
Biotinyl group displayed in red outline. 
 
 
 
Peptide effects on virus were determined by treating gradient-purified HIV-1BaL with increasing 
concentrations of peptide in cell infection and p24 release analyses. We found that Bt-KR13 and 
Bt-KR13b were both powerful inhibitors of HIV-1 infection comparable to that of 1 and 11 as 
displayed by their respective IC50 values of 136 ± 44 nM and 186 ± 38 nM. Additionally, Bt-KR13 
induces p24 release as efficiently as its parent peptide, KR13, 0.99 ± 15 µM and 1.63 ± 16 µM 
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respectively (Figure 25A and B).  Neither Bt-KR13b nor 11 caused p24 leakage as expected due 
to the unavailability of a free thiol because of the acetamidomethyl - sulfhydryl protection on their 
respective cysteine residues. 
 
 
 
 
 
 
 
Figure 25. Functional Characterization of PTT Biotinylated variants on HIV-1BaL pseudovirus antiviral 
functions. (A) Inhibition of cell infection analyzed using a single round pseudotyped assay.  The IC50 values 
of Bt-KR13 and Bt-KR13b inhibit HIV-1BaL infection to the same extent of their parent peptides, 136 ± 44nM 
and 186 ± 38 nM.  (B) Relative p24 release measured using ELISA. The calculated EC50 values for 1 and Bt-
KR13 were 0.989 ± 15 µM, 1.63 ± 16 µM respectively. 11 and Bt-KR13b did not display p24 lysis at 200 
µM. The data were normalized using untreated virus as a negative control (< 5% p24 release), and p24 release 
observed with 1% triton X treated virus was taken as 100% p24 content.  Sigmoidal curve fits of data were 
obtained using Origin v.8.1 (Origin Lab, Northampton, USA). Error bars represent standard deviation of the 
mean, n = 3.   
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3.2.3 Bt-KR13 effects on gp120 and HIV-1BaL 
 
After confirming that Bt-KR13 exhibited potencies similar to previous peptide triazoles by several 
characterization assays, we aimed to analyze the effect of the biotinylated peptides’ Cys residue on 
gp120, by exploiting the biotin group for detection.  The biotinylated peptides were incubated with 
soluble YU2 gp120, then the peptide/gp120 mixture was fractionated on a non-reducing gel along 
with several peptide controls also incubated with gp120, including a thiol-blocked variant, 11.  
Separate western blots were performed to detect the presence of gp120 and biotin.  We found that 
gp120 was present in all samples, however the only biotin detected was that of the Bt-BSA controls 
and a biotin blot in BT-KR13/gp120 mixture, which was at the same molecular weight of gp120 
(Figure 26A and B).  
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Figure 26. Non-Reducing Western Blot of Bt-KR13 Incubation with HIV-1BaL. (A) anti- Gp120 and (B) anti-
Biotin western blot of peptide samples Bt-KR13, KR13, and KR13b.  Bt-KR13 detected at the gp120 MW 
under non-reducing conditions, however peptides without a free SH group were not detected with gp120. 
Yu2 gp120 and Biotinylated-BSA were used as gp120 and biotin controls, respectively.   
 
 
 
Next, we repeated the Western blot detection under reducing conditions, to analyze the effect of 
the peptide attachment to gp120.  Here we observed biotin detection of the Bt-BSA controls, 
however the biotin positive band was not detected in the Bt-KR13/gp120 mixture (Figure 27) 
suggesting that the disulfide bond between peptide and protein was cleaved.   
 
Furthermore, to ensure that the biotin positive band we observed was due to a specific covalent 
attachment between the peptide thiol and gp120, we performed several control experiments 
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utilizing the non-thiol containing peptide (12, UM15).  Peptide 12 at a concentration of 5 µM and 
50 µM was co-incubated with a 5 µM concentration of Bt-KR13 and gp120 simultaneously.  The 
western blot analysis of biotin detection showed that 12 competed with Bt-KR13 binding to gp120, 
once again confirming that the IXW pharmacophore of peptide triazoles specifically binds gp120, 
yet the sulfhydryl group is responsible for the covalent attachment (Figure 28).  In addition, we 
performed a Western Blot using a biotinylated peptide with a blocked thiol group, denoted Bt-
KR13b, to once again confirm the specificity of the thiol group. Bt-KR13b was co-incubated with 
gp120 and was then run on a 12% non-reducing gel, followed by Western blot analysis to detect 
gp120 and biotin.  Biotin was not detected in the Bt-KR13b sample, thereby again displaying that 
a functional free thiol is required for covalent attachment (Figure 28).  These results with soluble 
gp120 were similar to those using pseudotyped HIV-1BaL virions. 
 
 
 
 
 
Figure 27. Reducing Western Blot of Bt-KR13 Incubation with HIV-1BaL. (A) anti- Gp120 and (B) anti-
Biotin western blot of peptide samples Bt-KR13, 1 (KR13), and 11 (KR13b).  Bt-KR13 no longer detected 
at the gp120 MW under reducing conditions. Yu2 gp120 and Biotinylated-BSA were used as gp120 and 
biotin controls, respectively.   
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Figure 28.  Western Blot of 12 (UM15) Competition with Bt-KR13 Incubation with HIV-1BaL. Biotin 
detection in peptide samples Bt-KR13 with increasing concentrations of 12. 1 (KR13), 11 (KR13b), and 
Biotinylated-BSA were used as controls. 
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Figure 29. Non-Reducing Western Blot of Bt-KR13b Incubation with HIV-1BaL. (A) anti- Gp120 and (B) 
anti-Biotin western blot of peptide samples Bt-KR13, KR13, and KR13b.  Bt-KR13b not detected at the 
gp120 MW under non-reducing conditions, nor are the peptides without a free SH group are detected with 
gp120. Yu2 gp120 and Biotinylated-BSA were used as gp120 and biotin controls, respectively. 
 
 
3.2.4 Effects of KR13 on disulfide mutations of HIV-1BaL 
 
To further investigate PTT-induced lysis, we aimed to identify specific gp120 disulfides involved 
in the lytic process. Therefore, we examined the role of several conserved cysteine residues which 
form disulfide bonds in gp120 and gp41.  Based on the thiol trajectory of the PTT-gp120 docked 
structure in our MD model, V3 region disulfide bonds were of great interest.  The peptide Cys 
residue approached disulfide linkages C378-C445, C385-C415 and C296-C331. These disulfides 
are commonly referred to as the “CD4 exposed disulfide cluster” due to their proximity to the CD4 
binding site, thereby making them potential sites of disulfide exchange in the virus infection 
process. For that reason, we mutated each cysteine residue in a single disulfide pair to yield mutant 
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HIV-1BaL virions.  We prepared intact viruses for the gp120 disulfides, C296E-C331K, C378S-
C445S and C385V-C415S.  Taking into consideration previous findings that displayed that KR13 
induces 6-helix bundle formation in gp4170, we also mutated gp41 disulfide C598-C604A to yield 
the C598A-C604A mutant. These mutant virions were gradient purified as previously described 
and quantified for gp120 and p24 content.  Mutant HIV-1BaL virions were tested for infectivity and 
displayed low infection levels, therefore we examined the ability of the mutant virions to bind sCD4 
and co-receptor surrogate, 17b, by ELISA.  The ELISA displayed that the mutant virions were 
capable of binding sCD4 and 17b to various extents (Figure 30).   
 
 
 
 
 
 
Figure 30. ELISA CD4 and 17b Binding of HIV-1BaL pseudovirus disulfide mutants. Sandwich ELISA used 
to determine binding potencies of immobilized virus to anti-CD4 and mAb 17b antibodies. Percent binding 
values were normalized based on the p24 content of each mutant and the gp120 content. Error bars represent 
standard deviation of the mean, n = 3. Bailey et al. 2015. 
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We performed p24 release analysis of peptide 1 treated mutant virions and displayed that 1 
maintained lytic potency comparable to WT HIV-1BaL in mutant HIV-1BaL C378S-C445S and 
C385V-C415S virions.  Strikingly, HIV-1BaL mutations C296E-C331K and C598A-C604A 
repressed p24 release normally elicited by 1 (Figure 31).   
 
 
 
 
 
 
 
Figure 31. Effect of HIV-1BaL disulfide mutations on p24 release by 1.   Effect of HIV-1BaL mutations C296E-
C331K (magenta) C378S-C445S (blue), C385V-C415S (cyan), and C598A-C604A (red) on p24 release. 
Relative p24 release was measured using ELISA.  The data were normalized using untreated virus as a 
negative control (< 5% p24 release), and p24 release observed with 1% triton X treated virus was taken as 
100% p24 content. Sigmoidal curve fits of data were obtained using Origin Pro.8 (Origin Lab). Error bars 
represent standard deviation of the mean, n = 3. Bailey et al. 2015. 
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These data imply that PTT- induced lysis is initiated within gp120 at C296-C331 and the role of 
the gp41 disulfide, C598-C604A, is to stabilize the 6 helix bundle for virolysis.  We suggest the 
latter because C598-C604 links the N and C-helices of gp41, which is critical for the proper 
structural and functional rearrangements of Env and previous studies have shown that an intact 
gp41 disulfide is a prerequisite for fusion and infection99,100.   However, we do recognize that our 
data do not determine the redox state of the gp41 disulfide, therefore it cannot be ruled out that 
C598-C604A is reduced during PTT-induced lysis.  
 
 
3.3 DISCUSSION 
 
The release of the capsid p24 protein caused by peptide triazole thiols led us to investigate the 
virucidal mechanism of action of peptide triazole thiols. We hypothesized that upon peptide Cys-
SH encounter with HIV-1 Env, the thiol interferes with conserved disulfides clustered proximal to 
the CD4 binding site in gp120 through “disulfide exchange”, ultimately leading to a rearrangement 
of the Env protein spike and disrupting the viral membrane. Based on our prior conclusions that 
displayed the importance of the V3 region of gp120, an area populated by several disulfide clusters, 
we examined the contribution of these disulfides to PTT-induced virolysis.  In agreement with our 
proposed hypothesis of a PTT-triggered disulfide exchange reaction within gp120, we found that 
virions pre-treated with reducing agents DTT or TCEP prior to peptide treatment displayed 
augmented p24 release profiles. We also showed by mutagenic analysis of conserved HIV-1 
envelope disulfides, that gp41 has an undefined role that is implicated in the lytic process.   
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To understand disulfide exchange in the context of PTT viral lysis, we assessed the effect of 
reducing agents on p24 release. DTT and TCEP pre-treated virions did not lose viral infectivity 
after reagent removal (Figure 22A), conversely the treated and washed virions displayed enhanced 
PTT- induced lysis (Figure 22B and C).  The reductive enhancement caused by DTT and TCEP 
was diminished when those virions were subsequently treated with IAAm (Figure 22D). These 
results provide evidence that reducing agents, DTT and TCEP, produce free sulfhydryl groups 
within gp120 and these thiols are used to catalyze the disulfide exchange cascade.   
 
The gp160 envelope protein contains 10 disulfide linkages; nine of these are found in gp120 and 
the last is within gp41.  Our previous docking analysis of PTT truncate, 8, complexed with gp120, 
placed the peptide SH group at an equidistant location from the disulfides C378-C445 (C3), C385-
C415 (C4), C296-C331 (V3). For this reason we explored the participation of these disulfides in 
the PTT lysis process by mutagenic analysis.  We found that p24 release capability by 1 was 
retained in disulfide mutants C378S-C445S and C385V-C415S, but mutants C296E-C331K and 
C598A-C604A abolished lytic potency of 1 (Figure 31).  The C296-C331 disulfide is located in 
the V3 loop, a region of gp120 which is displaced upon receptor binding to allow for further 
conformational changes of gp120 required for viral fusion. The C598-C604 disulfide is in a critical 
location of gp41, found in a loop between the N- and C- helices of the viral transmembrane protein. 
After engaging CD4, gp41’s N- and C- helices reorganize to form a 6-helix bundle.  The 6-helix 
bundle conformation is needed for virus fusion with host cells, thereby making these regions 
essential in the HIV infection process.   
 
 
In all, these results collectively show that disulfide disruption is an integral part of the PTT lytic 
mechanism. We speculate that PTTs initiate a cascade of disulfide exchange reactions from gp120 
to gp41, which subsequently induces 6-helix bundle formation, leading to lysis. This proposed 
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mechanism is buttressed by research showing that 6-helix bundle formation occurs during PTT-
induced lysis70.  In prior work, we found that Enfuvirtide, the fusion inhibitor that blocks 6- helix 
bundle assembly by targeting the N-terminal heptad repeat region of gp41, inhibits PTT-induced 
lysis. Enfuvirtide inhibition of virolysis suggests a relationship between viral membrane disruption 
and gp41 fusion-6 helix bundle formation.  These findings have led us to believe that virolysis 
induced by PTTs is related to the native physiological events, within the Env trimer, which require 
triggering gp41 fusion machinery through the viral membrane. Investigating the mechanism of 
virolysis will provide insight into understanding how the chemical perturbation of the HIV Env 
protein results in HIV membrane destabilization.  Additionally, understanding the virolytic 
mechanism will identify residues of Env that need to be targeted to optimize our entry inhibitors.  
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Chapter 4: Other Experiments 
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4. Introduction 
 
Peptide triazole thiols were first developed by Dr. Kantharaju Kamanna, with the intention of 
utilizing the C-terminal cysteine residue as a strategy for peptide conjugation to gold 
nanoparticles94. The lytic effect of these inhibitors, a surprising finding on their own, led us on a 
quest to understand the mechanism of action and to use the lytic feature to develop other novel anti-
HIV drug candidates.  The experiments described below were aimed towards both of these thrusts 
and represent ongoing efforts in the Chaiken lab. 
 
4.1 MATERIALS AND METHODS 
 
4.1.1 Peptide Synthesis and Click Conjugation  
 
All sequences and denotations of peptides reported are given in Table 1.  Peptides were synthesized 
manually by stepwise solid-phase peptide synthesis (SPPS) and purified as described in Chapter 2.  
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4.1.2 Western Blot Analysis of PTT interaction with BG505 SOSIP.664 gp140 
 
20 µM and 100 nM KR13 were incubated with BG505 SOSIP.664 gp140 as well at 37 °C for 35 
min at 23 °C.  After the incubation, a non-reducing western blot analysis was performed by adding 
15 µL of reaction samples to 15 µL of 1x Laemmli buffer.  Incubation of 20 µM UM15 was used 
as a negative control as well as 100 nM SOSIP and YU2 gp120. Gp120 was detected with 1:3000 
dilution of anti-gp120 D7324 (Aalto) and anti-sheep IgG conjugated HRP (Life Technologies). 
 
4.2 RESULTS 
 
4.2.1 KR13 Effects on BG505 SOSIP.664 gp140 
 
Previously, we aimed to determine if PTT-induced disulfide exchange initiated a cascade from 
gp120 disulfides to those in gp41. The SOSIP.664 trimer was used as a tool to investigate disulfide 
exchange.  SOSIP.664 is a soluble cleaved gp140 trimer, composed of gp120 and the ectodomain 
of gp41 (gp41ecto) in which the hydrophobic MPER sequence is removed101 (Figure 32).  Like the 
native envelope glycoprotein, SOSIP.664 has exposed epitopes that generate bNabs capable of 
neutralizing gp140 trimers.  This is attributed to the T332N substitution, which yields a glycan 
needed for epitope recognition by several bNabs101.  Additionally, SOSIP.664 is unique from other 
trimer mimics in that it is a stable variant. This was achieved by an I559P mutation, as well as the 
introduction of a mutant disulfide bond at position A501C-T605C which covalently connects gp120 
and gp41101 (Figure 32).   
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Figure 32. Design of BG505 SOSIP.664 gp140 trimer.  Linear representation of BG505 SOSIP.664 gp140 
trimer.  Several modifications displayed including A501C-T605C, T332N, and I559P. These substitutions 
are required for stability and production of bNabs of envelope trimer. 
 
 
 
 
 
Figure 33. Effect of peptide triazole treatment on gp140 SOSIP.664. KR13 and the non-thiol containing 
peptide triazole, UM15, were incubated with SOSIP prior to analysis by (A) Coomassie staining and (B) 
Western Blot analysis. 
90 
 
 
 
 
 
 
Figure 34. Effect of peptide triazole treatment on gp140 SOSIP.664. KR13 and the non-thiol containing 
peptide triazole, UM15, were incubated with SOSIP prior to analysis by (A) Coomassie staining and (B) 
Gp120 and gp41 Western Blot analysis. 
 
 
The cleavage of the A501C-T605C disulfide conjoining gp120 and gp41ecto would be readily 
detected by the separation of these proteins, thereby making it a useful tool to analyze PTT induced 
disulfide reduction. We found that SOSIP.664 treatment with PTT caused cleavage of the gp140 
trimer into the monomeric proteins, gp120 and gp41ecto (Figure 32 and 33) by disruption of the 
mutant SOS disulfide, A501C-T605C. However, it is important to note that the A501C-T605C 
disulfide which links gp120 and gp41 in SOSIP.664 is not native to HIV-1 Env, but its placement 
is in the same gp41 region of the naturally occurring gp41 disulfide, C598-C604.  From our data it 
is not possible to conclude how PTTs cause disulfide bond cleavage in SOSIP. For example, it is 
very possible that the cysteine SH group of 1 merely cleaves the A501C-T605C disulfide as a 
reducing agent, much as DTT would. To fully determine the mode of the gp140 cleavage, future 
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work must include KR13S, a scrambled PTT, treatment with SOSIP.664 to assess the specificity 
of the disulfide cleavage. 
 
4.3 Optimizing PTTs for enhanced proteolytic stability and formulating vehicles for 
delivery 
 
4.3.1 Synthesizing non-natural virolytic peptides  
 
Peptide triazoles hold great therapeutic promise as entry inhibitors, however in peptide form they 
are unstable.  Therefore, we must develop new methodologies to optimize the proteolytic stability 
of PTTs, thereby making them accessible to HIV patients.  The first method for increasing the 
stability of these peptides is to develop non-natural peptides.  This can be achieved by replacing 
natural L-amino acids with their D-amino acid counterparts and also utilizing amino acid analogs.  
The rationale behind these studies is that these substitutions were based on the hypothesis that 
limiting peptide bonds would make the inhibitors less recognizable to proteases.  By replacing the 
natural residues of UM-24 with D-amino acids and substituting Bta for Trp, a non-natural mimic 
of UM-24 was produced, denoted KR-42, as well as KR-42’s lytic variant containing a C-terminal 
Cys, denoted LB-07 (Table 4).  KR-42 displayed a reduced inhibition profile in comparison to its’ 
parent peptide, UM-24, however adding the cysteine residue (LB-07) regained potency comparable 
to UM-24, thereby reaffirming the significance the thiol group.   
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Table 4. Non-Natural Peptide Triazoles and Corresponding Amino Acid Sequences. 
 
 
 
 
 
Pilot studies were planned to investigate the proteolytic stability of natural PTs, non- natural PTs, 
and non-natural virolytic PTs.  Initial peptide digestion studies performed by former PhD 
Candidate, Pamela Kubinski, using a 1:20 weight ratio of protease to peptide revealed a rapid 
degradation of the natural peptide UM-24 (Figure 35).  Although Trp substitution with Bta and D-
amino acid replacement did produce peptides with reduced proteolytic stability profiles, they have 
also shown to be less potent than their natural L-amino acid counterparts.  Protease studies of non-
natural virolytic PTs have yet to be completed.  Therefore, we must explore other strategies to 
target stability, yet do not compromise potency.  Importantly, such a strategy has recently been 
accomplished in the Chaiken lab102, with the discovery of macrocyclic peptide triazoles. 
 
Peptide Amino Acid Sequence 
UM-24 LCit, LAsn, LAsn, LIle, AzidoPro, LTrp, LSer, NH2   
KR-41 LCit, LAsn, LAsn, LIle, AzidoPro, LBta, LSer, NH2  
KR-42 DCit, DAsn, DAsn, DIle, AzidoPro, LBta, DSer, NH2   
LB-07 DCit, DAsn, DAsn, DIle, AzidoPro, LBta, DSer, LCys, NH2 
LB-08 DCit, DAsn, DAsn, DIle, AzidoPro, LBta, DSer, DCys, NH2 
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Figure 35. Natural and non-natural peptide percent degradation over 25 hours.  Exposure of peptides UM-
24 and its non-natural counterpart, KR-42, to α-chymotrypsin resulted in >95% degradation of UM-24 after 
30 min, compared to retention of 75% of undigested non-natural peptide, KR-42, after 30 min. Trytophan 
analog (L-Bta), found in KR-42, resisted protease degradation. Data acquired from Pamela Kubinski. 
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CHAPTER 5: Future Directions 
 
 
 
 
 
 
 
 
 
 
 
95 
 
5. Introduction 
 
The work described herein uncovering the mechanism of peptide triazole thiols has made defining 
contributions to the HIV field.  The value of this research was recognized by the National Institute 
of Health, which awarded me an F31 Ruth Kirchstein fellowship to complete this exploration of 
gp120 disulfide dynamics in the HIV-1 antagonism.  As previously explained, peptide triazole 
thiols irreversibly inactivate HIV-1 virions by their ability to cause gp120 shedding and virolysis, 
thereby making them novel inhibitors.  As a result of the work elaborated in this thesis, we have 
made several conclusions regarding the virolytic mechanism of PTTs.  We have determined the 
following, (a) The lytic action of PTTs is not a mere function of peptide self-dimerization, instead 
viral lysis requires a free thiol. (b) Lytic action is dependent on the length of the C-terminus linker. 
(c) Finally, one of the most significant outcomes of this project, PTTs cause virolysis by inducing 
exchange of gp120 disulfides.   
 
 Although, we determined a significant amount regarding the structure-activity relationship of 
PTTs and their mechanism of action, there is still more to be determined.  These innovative 
inhibitors have a broad scope of utility for their potential as drug candidates as well as their role in 
vaccine development. Furthermore, PTTs have shed light on disulfide exchange, a process not 
frequently discussed as a feature of viral entry.  Attaining a more detailed understanding of virus-
related disulfide exchange will help propel rational design of drugs and provide researchers with a 
more holistic view of lentiviral infection. 
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5.1 Therapeutic Delivery of Peptide Triazoles  
 
5.1.1 Pegylated Liposomal Delivery of NNPTs 
 
Despite the efficacy of HAART, there is still a pressing need for a long-acting HIV drug.  To this 
end, we aim to develop an effective, yet safe formulation for PTT delivery. Therefore, as described 
above, we used the combined synthesis and functional screening to identify a structure-minimized, 
maximally non-natural peptide triazole virucide (NNPT) and to design its scale-up synthesis as a 
lead microbicide development candidate.  We further aimed to derive a hydrogel-encapsulated form 
of the NNPT virucide and identify formulations for in vivo testing.  Anti-retrovirals have previously 
been delivered by using liposome encapsulation methods. This has proven to be an advantageous 
strategy for delivery because it offers multiple layers of protection for the drug.  Liposomes prevent 
peptide/drug degradation while in transport. Additionally, liposomes can be modified with 
polymers, such as polyethyleneglycol (PEG), which protect the liposomal integrity.  Decorating 
encapsulated liposomes with sCD4 and 17b co-receptor surrogate, will specifically engage HIV 
particles (Figure 36).  After engagement, controlled release of PTT entry inhibitors will exert their 
mechanism of action causing irreversible viral inactivation. Therefore, Dr. Rachna Arora has been 
leading studies in hopes of developing HIV-1-targeting liposome formulations. These pegylated 
liposomes represents another potential use of PTTs due to their ability to inactivate virus in the 
absence of cells. 
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Figure 36. Proposed mode of action of pegylated liposomal drug delivery vehicle. Image by Rachna Arora. 
 
 
5.2 Understanding the Role of Disulfide Exchange in viral entry processes  
 
5.2.1 The Role of Thiols in Regulating Viral Entry 
 
HIV-1 and other enveloped viruses require a series of coordinated conformational rearrangements 
of the viral envelope and transmembrane proteins to ensure efficient viral infection. These 
synchronized chemical and structural changes between the viral and host cell proteins are regulated 
by a myriad of factors which ultimately result in transfer of the viral genetic material into target 
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cells. The role of thiols as a means of regulation in virus entry processes is a new field, yet growing 
evidence suggests that many viruses utilize thiol-disulfide exchange reactions as a sensory 
mechanism to enhance viral entry.  Several lentiviruses including, Sindbis virus (SV), murine 
leukemia virus (MLV), human T-cell lymphotropic virus (HTLV-1), and HIV-1 appear to execute 
disulfide cleavage by thiol-exchange during their respective viral entry processes100,103,104.  This 
reliance on redox-induced changes to their disulfides is an additional layer of regulation to ensure 
successful viral membrane fusion. 
 
5.2.2 Oxidoreductase Activity Involvement in Viral Thiol Exchange 
 
Gp120 disulfide exchange has been previously observed and may be an integral step in native HIV 
entry.  Mounting evidence96,105-107 has demonstrated that oxidoreductase inhibition impairs HIV 
infection, CD4 binding, and fusion events, thereby implicating redox exchange as a mechanism 
used in HIV entry. Oxidoreductases are a class of enzymes that utilize cofactors, NADP or NAD+, 
to transfer electrons from one molecule to another (Figure 37) 108.  
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Figure 37. Electron flow displaying the reductive recycling of NADPH and NAD utilized by cellular 
oxidative proteins. Reductase systems shown are the thioredoxin (Trx) system, including thioredoxin 
reductase (TrxR); the glutathione (GSH) system, including glutathione reductase, which recycles oxidized 
glutathione (GSSG). Also included are the microbial reductase systems. 
 
 
 
 
The body uses oxidoreductases to catalyze the formation and cleavage of disulfide bonds in cells. 
Common oxidoreductases are thioredoxin (Trx) and protein disulfide isomerase (PDI), known for 
their catalysis of thiol-disulfide exchange reactions employed in the protein maturation process in 
the endoplasmic reticulum.  However, oxidoreductases also are commonly trafficked to the cell-
surface and exert their catalytic functions in disulfide cleavage of surface-bound macromolecules 
and viral proteins.  One of the first studies that alluded to the reductive function of mammalian cells 
was the analysis of the activation of the diphtheria toxin (DT) protein109.  DT is a homodimer linked 
by a disulfide bridge, which is cleaved upon binding to its cell surface receptor.  The disulfide 
cleavage activates DT, thereby enabling the protein to exert cytotoxic properties109. Intriguingly, 
the membrane impermeant thiol reagents p-chloromercuribenzene sulfonate (pCMBS) and 5,5'-
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dithiobis-(2-nitrobenzoic acid) (DTNB) were found to inhibit the reductive cleavage of DT, thereby 
preventing cytotoxicity109. More recently, PDI inhibitors and monoclonal antibodies to PDI have 
shown similar inhibitions, suggesting that the reductive cleavage events on the cell membrane are 
attributed to PDI110.  
 
Further analysis of these thiol blocking reagents has shown that DTNB inhibits Sindbis and HIV 
infection in a dose- dependent manner. Both of these viruses contain many disulfide bonds.  It is 
postulated that DTNB and other thiol reagents inhibit the cleavage of viral disulfide bonds that are 
required for infection, which implies that cell surface redox activity is a requirement of viral entry.  
Furthermore, the IC50 values of HIV inhibition by DTNB is comparable to its IC50 value for PDI 
inhibition87.  These data suggest that DTNB inhibits HIV infection by inhibiting PDI, leading to 
the hypothesis that gp120 disulfide cleavage is required for viral entry. Further buttressing this 
argument is research from Markovic et al., which displayed that only oxidized gp120 is capable of 
binding to CD4 and co-receptor111. After these binding events, the resulting gp120 has 4 free thiols, 
indicating that 2 disulfides are reduced during HIV entry111. 
 
In all, the disulfide-exchange literature is vast and diverse; and although cell-surface secreted 
oxidoreductases are implicated in the process, there are still many lingering questions.  There has 
been much debate in literature regarding whether cell lines utilize various oxidoreductase enzymes 
or if a single oxidoreductase is the sole initiator of these reactions96. Also, it is still unknown if 
oxidoreductases directly undergo disulfide exchange with gp120 disulfides or if other partners are 
involved.  Cerutti et al. showed that the gp120 binding to CD4 required a reduced disulfide in either 
domain 1 or domain 2 of the latter105. These results suggest that membrane-associated 
oxidoreductases “prime” CD4 for gp120 interaction and suggest the possibility that the redox state 
of the CD4 receptor is critical to HIV entry.  Moving forward, it will be useful to identify the 
oxidoreductase involvement in HIV entry by comparing the PTT antiviral potencies with various 
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PDI–deficient cell lines in antiviral infection assays. Additionally, useful information will be 
obtained from characterizing structural details of CD4 domains and determining gp120’s CD4 
redox preference during virus entry. 
In an effort to further elucidate the role of disulfide exchange in HIV entry, previous researchers 
have used active site mutants of PDI to capture the mixed disulfide intermediate of PDI and its 
substrate, gp120.  These results showed that PDI formed a covalent disulfide cross-linked 
intermediate with soluble gp120 protein, which was not observed in the presence of PDI 
inhibitors112. Together, these results provided additional evidence of the role of disulfide exchange 
in HIV entry.  Although PDI and Trx are the most common oxidoreductases implicated in 
facilitating viral entry, there has not been a robust study evaluating the utility of the entire 22 
subclasses of these enzymes and their effects on virus entry. Therefore, assessing HIV infectivity 
capability on cell lines that are deficient of oxidoreductases through the use of siRNAs or 
CRISPR/Cas9 technology, may further clarify their roles. 
 
Additional experiments may include detecting and quantifying free sulfhydryls of gp120 before 
and after its incubation with cell lines expressing PDI and PDI-deficient cell lines.  The thiols of 
gp120 can be quantified by the use of a maleimide biotin probe followed by a co-
immunoprecipitation pull-down assay with Streptavidin-HRP to retrieve and visualize the protein. 
 
What is known is that the conserved disulfides of the HIV envelope are pertinent to CD4 binding, 
gp120 binding, and infectivity97,113. It is also known that thiol-exchange is a prerequisite for CXCR4 
tropic HIV entry111 and because cell membrane oxidoreductases are readily accessible to Env 
disulfides, their enzymatic function is linked to disulfide exchange114.   
 
 
102 
 
5.3 Understanding Disulfide Exchange in the context of PTT Lysis 
 
5.3.1 Identify occurrence and nature of covalent attachment of PTT to gp120 during virus 
lysis 
 
We were able to define the mechanism of action of PTTs as “disulfide exchange” through the use 
of various methodologies.  Western blot analysis allowed us to determine that PTTs covalently bind 
Env, however we still have not been able to determine the specific disulfide contact site on gp120 
that is targeted for covalent attachment by the PT-SH group.   Therefore, future studies of PTTs 
will include pinpointing and displaying PTT attachment to a defined disulfide site of Env.  Mass 
spectroscopy digestion assays utilizing the biotinylated PTTs, Bt-KR13 and Bt-KR13b, will be 
useful tools.  These peptides can be used to form conjugates with gp120, followed by trypsin 
digestion, and subsequent LC-MS/MS, can then be used to detect peptides corresponding to Cys 
containing regions of gp120. 
Furthermore, identifying the path of disulfide exchange induced by PTTs may also be accomplished 
through the use of affinity labeling techniques.  Another option to detect PTT attachment to gp160 
is using Activity-Based Protein Profiling (ABPP), a synthetic methodology where probes contain 
a reporter tag, C-terminal reactive group, and a peptide pharmacophore that targets the protein of 
interest.  To identify the contact site of PT- thiol engagement, ABPP probes can be designed and 
then incubated with gp160.  Such probes can be designed so that they contain the characteristic 
peptide triazole, IXW pharmacophore, a photocrosslinker for the reactive group would allow the 
labeling of gp120 disulfides/cysteines and this covalent attachment could easily be visualized by 
in-gel fluorescence scanning by using a rhodamine group for the reporter tag. Benjamin Cravatt 
displayed the utility of the ABPP approach in verifying target identification in several structurally 
diverse proteins 115. 
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5.3.2 Further identify HIV-1 Env Cysteine mutations involved in PTT lytic mechanism  
 
The findings of PTT-induced disulfide exchange were intriguing, however there are still facets of 
the cascade process that are unknown. We still do not know the exact path of disulfide exchange. 
Further we do not know if PTT-induced virolysis yields a single disulfide exchange reaction or 
multiple reactions resulting in a cascade. To address these questions combinatorial disulfide 
mutagenesis experiments in HIV-1 Env will be useful.  Performing p24 release assays with gp120 
containing multiple cysteine mutations may help to identify the regions of gp120 responsible for 
PTT-induced lysis and explain the path of disulfide exchange. 
 
 
5.3.3 Analyzing 6 helix bundle formation after PTT treatment in comparison to native 6 
helix bundle formation after cell-fusion events 
 
 
Additionally, we found that mutating the gp41 disulfide led to inefficient virolysis, thereby 
suggesting the role of disulfide exchange in the native cell-fusion process. The discovery of the 
involvement of the gp41 disulfide in PTT-induced virolysis was striking due to previous findings70 
which displayed MPER exposure after virus-PTT treatment.  These results taken together advocate 
for our current working model of PTT mechanism of action (Figure 38).  We propose that PTTs 
trigger disulfide exchange in gp120 , which leads to a conformational change in  the HIV envelope 
that has similar structural properties to that occurring in the virus cell fusion process70.  Analysis 
of the native 6-helix bundle formation in comparison to the 6-helix bundle thought to be induced 
by PTT treatment is necessary to more clearly define the structural mechanisms induced by PTTs.   
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In particular, the hydrophobic gp41 loop region is of special interest.  This region contains a 
characteristic CXXKXXC amino acid sequence found in the fusogenic proteins of numerous 
retroviruses116-118. In turn, this suggests a conserved mechanistic role of this sequence in the fusion 
process.  Furthermore, the basic amino acid, Lysine 601, centered in the conserved sequence is 
hypothesized to provide a balance of polarity and hydrophobicity that allows for the proper 
functioning of the gp41 loop during membrane fusion99.  Previously, gp41 peptides consisting of 
K601 mutations, have shown the importance of a basic residue, such as Lys or Arg in the gp41 
loop, for efficient six-helix bundle formation and entry99.  However, alanine mapping mutagenesis 
of the CXXKXXC gp41 loop region in virus has yet to be analyzed.  Subsequent Env treatment 
with PTT will be a useful study to understand the virus-cell fusion process in the context the PTT 
mechanism.   
 
 
 
Figure 38. Working Model of Peptide Triazole Thiol Virolytic Mechanism of Action. PTTs hijack the fusion 
mechanism of the HIV entry process. PTT binding to Env initiates disulfide disruption in gp120, causing 
similar conformational arrangements that occur upon the virus fusion process. Gp41 fusion peptide is 
stabilized by C598-C604, which protrudes and ruptures the viral membrane, therefore causing HIV to release 
its cellular contents. Gp41 NHR (red), gp41 CHR (blue), viral membrane (grey), six-helix bundle (blue/red 
cylinder), disulfide region-DSR (dark green), MPER (lime green). Image from Andrew Holmes. 
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Appendix 
 
Appendix Figure 1. Peptide 1a Chromatogram 
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Appendix Figure 2. Peptide 1a Mass Spectrum 
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Appendix Figure 3. Peptide 1 Chromatogram 
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Appendix Figure 4. Peptide 1 Mass Spectrum 
 
 
 
 
 
 
115 
 
Appendix Figure 5. Peptide 2 Chromatogram 
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Appendix Figure 6: Peptide 2 Mass Spectrum 
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Appendix Figure 7. Peptide 3 Chromatogram 
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Appendix Figure 8: Peptide 3 Mass Spectrum 
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Appendix Figure 9. Peptide 4 Chromatogram 
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Appendix Figure 10: Peptide 4 Mass Spectrum 
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Appendix Figure 11. Peptide 5 Chromatogram 
 
 
 
 
 
 
 
 
 
 
 
 
122 
 
Appendix Figure 12: Peptide 5 Mass Spectrum 
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Appendix Figure 13. Peptide 6 Chromatogram 
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Appendix Figure 14: Peptide 6 Mass Spectrum 
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Appendix Figure 15. Peptide 7 Chromatogram 
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Appendix Figure 16: Peptide 7 Mass Spectrum 
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Appendix Figure 17. Peptide 8 Chromatogram 
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Appendix Figure 18: Peptide 8 Mass Spectrum 
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Appendix Figure 19. Peptide 9 Chromatogram 
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Appendix Figure 20: Peptide 9 Mass Spectrum 
 
 
 
 
 
 
 
131 
 
 
Appendix Figure 21. Peptide 10 Chromatogram 
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Appendix Figure 22: Peptide 10 Mass Spectrum 
 
 
 
133 
 
 
Appendix Figure 23. Peptide 11 Chromatogram 
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Appendix Figure 24. Peptide 11 Mass Spectrum 
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Appendix Figure 25. Peptide 12 Chromatogram 
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Appendix Figure 26. Peptide 12 Mass Spectrum 
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Appendix Figure 27. Bt-KR13 Chromatogram (Prepared by SciLight Peptide) 
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Appendix Figure 28. Bt-KR13 Mass Spectrum (Prepared by SciLight Peptide) 
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Appendix Figure 29. Bt-KR13b Chromatogram 
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Appendix Figure 30. Bt-KR13b Mass Spectrum 
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Appendix Figure 31: Effects of sulfhydryl reagents on HIV-1BaL infectivity.  (A) DTT 
treated HIV-1BaL virions were treated with 0.02mM IAAM prior to adding HOS cells to 
measure infectivity. (B) Infectivity of HIV-1BaL virus pre-treated with 0.02mM IAAm for 
60 min.  All reagents were removed by centrifugation and PBS washing prior to adding 
additional reagents or adding to cells. 
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Appendix Figure 32. Lack of inhibition of 6-helix bundle formation by 2G12. Antiviral 
infection assay performed by adding virus to cells at 4 °C followed by subsequent serial 
dilutions of 2G12 at 37 °C to allow fusion. Fusion inhibitor, T20, displayed a dose 
dependent inhibition. 
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